Rennova Health (RNVA) 10-K 13 Feb 25 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Feb. 04, 2025	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-35141
Entity Registrant Name	RENNOVA HEALTH, INC.
Entity Central Index Key	0000931059
Entity Tax Identification Number	68-0370244
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	477 S. Rosemary Avenue
Entity Address, Address Line Two	Suite 222
Entity Address, City or Town	West Palm Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33401
City Area Code	(561)
Local Phone Number	855-1626
Title of 12(g) Security	Common Stock, $0.0001 Par Value
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 2,993,432
Entity Common Stock, Shares Outstanding		43,051,322,257
Documents Incorporated by Reference [Text Block]	None
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Opinion [Text Block]	We have audited the accompanying consolidated balance sheets of Rennova Health, Inc. (the Company) as of December 31, 2023 and 2022, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for the years ended December 31, 2023 and 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.
Auditor Name	Haynie & Company
Auditor Location	Salt Lake City, Utah
Auditor Firm ID	457

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 49,015	$ 499,470
Accounts receivable, net	3,087,420	3,110,969
Inventory	198,156	242,645
Prepaid expenses and other current assets	44,601	215,365
Income tax refunds receivable	837,460	837,460
Total current assets	6,944,959	6,363,162
Property and equipment, net	4,321,299	4,194,299
Intangible asset	259,443	259,443
Investment	8,192,476	9,016,072
Deposits	175,569	165,530
Right-of-use assets	359,194	574,256
Total assets	20,252,940	20,572,762
Current liabilities:
Accounts payable (includes related party amounts of $97,311 and $47,636, respectively)	12,371,566	11,204,305
Accrued expenses	15,399,268	19,384,803
Income taxes payable	1,589,244	1,348,425
Current portion of notes payable	1,026,758	2,917,390
Current portion of loan payable, related party	2,168,000	2,995,000
Current portion of debentures		8,622,240
Current portion of right-of-use operating lease obligations	183,345	215,063
Derivative liability	455,336	455,336
Current liabilities of discontinued operations	9,312,174	2,165,595
Total current liabilities	42,505,691	49,308,157
Long-term liabilities:
Accrued expenses	6,192,700
Debentures	8,222,240
Right-of-use operating lease obligations, net of current portion	175,849	359,193
Total liabilities	57,096,480	49,667,350
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.0001 par value, 250,000,000,000 shares authorized, 40,551,322,257 and 29,084,322,257 shares issued and outstanding, respectively	4,055,132	2,908,432
Additional paid-in-capital	1,670,425,144	1,671,571,834
Accumulated deficit	(1,711,306,941)	(1,703,577,780)
Total Rennova’s stockholders’ deficit	(36,823,749)	(29,094,588)
Noncontrolling interest	(19,791)
Total stockholders’ deficit	(36,843,540)	(29,094,588)
Total liabilities and stockholders’ deficit	20,252,940	20,572,762
Series H Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value
Series L Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	2,500	2,500
Series M Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	208	208
Series N Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	24	29
Series O Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	82	87
Series P Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	102	102
Related Party [Member]
Current assets:
Note receivable from related party	2,728,307	1,457,253
Current liabilities:
Current portion of loan payable, related party	$ 2,168,000	$ 2,995,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.01
Preferred stock, shares authorized	5,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000,000	250,000,000,000
Common stock, shares issued	40,551,322,257	29,084,322,257
Common stock, shares outstanding	40,551,322,257	29,084,322,257
Series H Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, stated par value	$ 1,000	$ 1,000
Preferred stock, shares authorized	14,202	14,202
Preferred stock, shares issued	10	10
Preferred stock, shares outstanding	10	10
Series L Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, stated par value	$ 1	$ 1
Preferred stock, shares authorized	250,000	250,000
Preferred stock, shares issued	250,000	250,000
Preferred stock, shares outstanding	250,000	250,000
Series M Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, stated par value	$ 1,000	$ 1,000
Preferred stock, shares authorized	30,000	30,000
Preferred stock, shares issued	20,810	20,810
Preferred stock, shares outstanding	20,810.35	20,810
Series N Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, stated par value	$ 1,000	$ 1,000
Preferred stock, shares authorized	50,000	50,000
Preferred stock, shares issued	2,404	2,900
Preferred stock, shares outstanding	2,403.78	2,900
Series O Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, stated par value	$ 1,000	$ 1,000
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	8,150	8,685
Preferred stock, shares outstanding	8,149.59	8,685
Series P Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, stated par value	$ 1,000	$ 1,000
Preferred stock, shares authorized	30,000	30,000
Preferred stock, shares issued	10,195	10,195
Preferred stock, shares outstanding	10,194.87	10,195
Related Party [Member]
Accounts payable	$ 97,311	$ 47,636

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net revenues	$ 18,685,845	$ 13,036,172
Operating expenses:
Direct costs of revenues	7,574,548	6,767,921
General and administrative expenses	9,435,031	7,217,405
Depreciation and amortization	310,528	469,371
Total operating expenses	17,320,107	14,454,697
Income (loss) from continuing operations before other income (expense), income taxes and net loss attributable to noncontrolling interest	1,365,738	(1,418,525)
Other income (expense):
Other income, net	1,151,754	433,353
Gain from forgiveness of debt	200,000	334,819
Loss from legal settlements, net	(755,117)	(129,153)
Change in fair value of investment	(823,596)
Interest expense	(1,452,823)	(2,257,544)
Total other income (expense), net	(1,679,782)	(1,618,525)
Net loss from continuing operations before income taxes, including noncontrolling interest	(314,044)	(3,037,050)
Provision for income taxes	(239,834)	(312,849)
Net loss from continuing operations, including noncontrolling interest	(553,878)	(3,349,899)
(Loss) income from discontinued operations	(7,195,076)	56,844
Net loss, including noncontrolling interest	(7,748,954)	(3,293,055)
Net loss attributable to noncontrolling interest	19,793
Net loss attributable to Rennova	(7,729,161)	(3,293,055)
Deemed dividends		(330,876,369)
Net loss available to common stockholders	$ (7,729,161)	$ (334,169,424)
Net loss per share of common stock available to common stockholders- basic and diluted
Continuing operations - basic	$ 0	$ (0.03)
Continuing operations - diluted	0	(0.03)
Discontinued operations - basic	0	0
Discontinued operations - diluted	0	0
Total basic	0	(0.03)
Total diluted	$ 0	$ (0.03)
Weighted average number of shares of common stock outstanding during the period:
Basic	32,825,519,517	9,992,238,468
Diluted	32,825,519,517	9,992,238,468

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Deficit - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2021	$ 20,451	$ 424	$ 1,342,085,957	$ (1,369,408,356)			$ (27,301,524)
Balance, shares at Dec. 31, 2021	2,045,201	4,244,700
Conversions of Series N Preferred Stock into common stock	$ (30)	$ 1,599,408	(1,599,378)
Conversions of Series N Preferred Stock into common stock, shares	(3,036)	15,994,077,566
Conversions of Series O Preferred Stock into common stock	$ (12)	$ 1,308,600	(1,308,588)
Conversions of Series O Preferred Stock into common stock, shares	(1,215)	13,086,000,000
Net loss				(3,293,055)			(3,293,055)
Conversion of Series F Preferred Stock into common stock	$ (17,500)		17,500
Conversions of Series F Preferred Stock into common stock, shares	(1,750,000)	1
Issuances of Series P Preferred Stock	$ 17		1,499,983				1,500,000
Issuances of Series P Preferred Stock, shares	1,650
Deemed dividends from issuances of Series P Preferred Stock			333,333	(333,333)
Payment of cash in lieu of fractional shares			(9)				(9)
Payment of cash in lieu of fractional shares, shares		(10)
Deemed dividends from triggers of down round provisions			330,543,036	(330,543,036)
Balance at Dec. 31, 2022	$ 2,926	$ 2,908,432	1,671,571,834	(1,703,577,780)	$ (29,094,588)		(29,094,588)
Balance, shares at Dec. 31, 2022	292,600	29,084,322,257
Conversions of Series N Preferred Stock into common stock	$ (5)	$ 551,700	(551,695)
Conversions of Series N Preferred Stock into common stock, shares	(496)	5,517,000,000
Conversions of Series O Preferred Stock into common stock	$ (5)	$ 595,000	(594,995)
Conversions of Series O Preferred Stock into common stock, shares	(535)	5,950,000,000
Sale of noncontrolling interest						2	2
Net loss				(7,729,161)	(7,729,161)	(19,793)	(7,748,954)
Balance at Dec. 31, 2023	$ 2,916	$ 4,055,132	$ 1,670,425,144	$ (1,711,306,941)	$ (36,823,749)	$ (19,791)	$ (36,843,540)
Balance, shares at Dec. 31, 2023	291,569	40,551,322,257

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss from continuing operations, including noncontrolling interest	$ (553,878)	$ (3,349,899)
Adjustments to reconcile net loss to net cash provided by (used in) operations:
Depreciation and amortization	310,528	469,371
Non-cash interest income	(90,653)	(212,819)
Original issue discount on debt		50,000
Gain from forgiveness of debt	(200,000)	(334,819)
Net loss from legal settlements	755,117	129,153
Change in fair value of investment	823,596
Loss on disposal of equipment		1,650
Income from federal government provider relief funds	(285,572)	(595,692)
Changes in operating assets and liabilities:
Accounts receivable	23,549	(343,446)
Inventory	44,489	37,868
Prepaid expenses and other current assets	84,172	(93,486)
Security deposits	(10,039)	22,284
Change in right-of-use assets	215,062	247,018
Accounts payable	1,167,261	(6,704)
Accrued expenses	1,126,971	3,686,494
Change in right-of-use operating lease obligations	(215,062)	(247,018)
Income tax assets and liabilities	240,819	312,849
Net cash provided by (used in) operating activities of continuing operations	3,436,360	(227,196)
Net cash (used in) provided by operating activities of discontinued operations	(48,497)	8,848
Net cash provided by (used in) operating activities	3,387,863	(218,348)
Cash flows from investing activities:
Capital expenditures	(350,934)	(35,230)
Note receivable / receivable from related party	(1,180,401)	(869,961)
Net cash used in investing activities of continuing operations	(1,531,335)	(905,191)
Net cash from investing activities of discontinued operations
Net cash used in investing activities	(1,531,335)	(905,191)
Cash flows from financing activities:
Proceeds from issuance of related party loans	580,000	1,050,000
Payments on related party loans	(1,407,000)	(182,000)
Proceeds from issuance of debentures		500,000
Payments of debentures	(400,000)	(150,000)
Payments on notes payable	(1,079,983)	(1,415,610)
Receivables paid under accounts receivable sales agreements		(688,235)
Proceeds from federal government provider relief funds		284,339
Proceeds from issuances of Series P Preferred Stock		1,500,000
Cash paid for fractional shares in connection with reverse stock split		(9)
Net cash (used in) provided by financing activities of continuing operations	(2,306,983)	898,485
Net cash from financing activities of discontinued operations
Net cash (used in) provided by financing activities	(2,306,983)	898,485
Net change in cash	(450,455)	(225,054)
Cash at beginning of period	499,470	724,524
Cash at end of period	$ 49,015	$ 499,470

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (7,729,161)	$ (3,293,055)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2023
Insider Trading Arrangements [Line Items]
No Insider Trading Flag	true

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Description of Business and Basis of Presentation	Note 1 – Description of Business and Basis of Presentation Rennova Health, Inc. (“Rennova”, together with its subsidiaries, the “Company”, “we”, “us”, “its” or “our”) is a provider of health care services. The Company owns one operating hospital in Oneida, Tennessee and a hospital located in Jamestown, Tennessee that it plans to reopen and operate. In addition, the Company owns a subsidiary providing services in the behavioral health sector on the campus of its hospital in Oneida, Tennessee. The Company’s operations consist of only one segment. Recent Events Subsequent to December 31, 2023, the Company sold several of its healthcare subsidiaries as more fully discussed in Note 18. Other recent events are also presented in Note 18. Scott County Community Hospital (d/b/a Big South Fork Medical Center) On January 13, 2017, we acquired certain assets related to Scott County Community Hospital, based in Oneida, Tennessee (the “Oneida Assets”). The Oneida Assets include a 52,000 6,300 4.3 1.0 Myrtle Recovery Centers, Inc. In the second quarter of 2022, the Company formed a subsidiary, Myrtle Recovery Centers, Inc. (“Myrtle”), to pursue opportunities in the behavioral health sector, initially in our core, rural markets. We are leveraging our existing physical locations and corporate and regional infrastructure to offer behavioral health services, including substance abuse treatment. Services are provided on either an inpatient, residential basis or an outpatient basis. On August 10, 2023, Myrtle was granted a license by the Department of Mental Health and Substance Abuse Services of Tennessee to operate an alcohol and drug treatment facility in Oneida, Tennessee. The facility, which is located at Rennova’s Big South Fork Medical Center campus, commenced operations and began accepting patients on August 14, 2023. The facility offers alcohol and drug residential detoxification and residential rehabilitation treatment services for up to 30 patients. On November 1, 2023, Myrtle began accepting patients at its recently opened Nonresidential Office-Based Opiate Treatment Facility (“OBOT”). The OBOT is located adjacent to Myrtle’s alcohol and drug treatment facility in Oneida, Tennessee and supplements the existing residential rehabilitation and detoxification services offered at Myrtle. On April 11, 2023, Myrtle sold shares of its common stock equivalent to a 1.961 Jamestown Regional Medical Center On June 1, 2018, we acquired from Community Health Systems, Inc. certain assets related to an acute care hospital located in Jamestown, Tennessee, referred to as Jamestown Regional Medical Center, for a purchase price of $ 0.7 90,000 eight The Company suspended operations at the hospital and physician practice in June 2019, as a result of the termination of the hospital’s Medicare agreement and other factors. The Company is evaluating whether to reopen the facility as an acute care hospital or as another type of healthcare facility. Jamestown is located 38 miles west of Big South Fork Medical Center. CarePlus Clinic On March 5, 2019, we acquired certain assets related to an outpatient clinic located in Williamsburg, Kentucky, known as CarePlus Clinic. The clinic and its associated assets, which were acquired from CarePlus Rural Health Clinic, LLC, offered compassionate care in a modern, patient-friendly facility. The CarePlus Clinic was located 32 miles northwest of our Big South Fork Medical Center. On January 31, 2024, the Company closed the CarePlus Clinic. Discontinued Operations During the third quarter of 2020, the Company made a decision to sell EPIC Reference Labs, Inc. (“EPIC”) and it also decided to discontinue several other non-operating subsidiaries. During the fourth quarter of 2024, the Company discontinued several additional non-operating subsidiaries. As a result, EPIC’s operations and the other non-operating subsidiaries’ liabilities have been included in discontinued operations for all periods presented. The Company was unable to find a buyer for EPIC and, therefore, it has ceased all efforts to sell EPIC and closed down its operations. Impact of the Pandemic Demand for services at our hospitals was substantially impacted by the COVID-19 pandemic. Moreover, the pandemic affected our ability to maintain adequate healthcare staffing levels which put pressure on salaries and wages and the need for higher cost, contract labor. The availability of healthcare supplies was limited, and supplies costs increased as well. Reduced demand and higher costs negatively affected our overall profitability and liquidity. Although the effects of COVID-19 have not been significant recently, a resurgence of COVID-19 in our markets could affect demand for services and increase our costs. In addition, government assistance programs may not be available as they have been in the past to address such near-term profitability and liquidity pressures. These developments had, and may in the future have, a material adverse effect on us and operations of our healthcare facilities. HHS Provider Relief Funds The Company received HHS Provider Relief Funds, which were provided to eligible healthcare providers out of the $ 100 13.6 13.3 0.3 0.6 4.4 8.0 0.3 As of December 31, 2023, the Company’s estimate of the amount for which it is reasonably assured of meeting the underlying terms and conditions of the grants was based on, among other things, the various notices issued by HHS on September 19, 2020, October 22, 2020, and January 15, 2021 and the Company’s results of operations during the years ended December 31, 2023, 2022, 2021 and 2020. The Company believes that it was appropriate to recognize a net of $ 13.3 13.3 The Company was served with a qui tam 1.2 Going Concern Under Accounting Standards Codification (“ASC”), Presentation of Financial Statements—Going Concern (Subtopic 205-40) At December 31, 2023, the Company had a working capital deficit and stockholders’ deficit of $ 35.6 36.8 7.7 3.3 The Company’s consolidated financial statements are prepared assuming the Company can continue as a going concern, which contemplates continuity of operations through realization of assets, and the settling of liabilities in the normal course of business. The Company’s current financial condition may make it difficult to attract and maintain adequate expertise in its management team to successfully operate its remaining healthcare facilities. There can be no assurance that the Company will be able to achieve its business plan, raise any additional capital or secure the additional financing necessary to implement its current operating plan. The ability of the Company to continue as a going concern is dependent upon its ability to raise adequate capital to fund its operations and repay its outstanding debt and other past due obligations, fully align its operating costs, increase its net revenues, and eventually gain profitable operations. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Reverse Stock Split On March 15, 2022, the Company effected a 1-for-10,000 10,000 Amendment to Certificate of Incorporation, as Amended Effective November 5, 2021, the Company filed an Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to provide that the number of authorized shares of the Company’s common stock or preferred stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the Company entitled to vote generally in the election of directors, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware (or any successor provision thereto), voting together as a single class, without a separate vote of the holders of the class or classes the number of authorized shares of which are being increased or decreased unless a vote by any holders of one or more series of preferred stock is required by the express terms of any series of preferred stock pursuant to the terms thereof. Increases in Authorized Shares of Common Stock Effective March 15, 2022, the Company increased the authorized shares of its common stock from 50 250

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation and Consolidation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and in accordance with Regulation S-X of the SEC. The consolidated financial statements include the accounts of Rennova Health, Inc. and its wholly-owned and majority-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Comprehensive Loss During the years ended December 31, 2023 and 2022, comprehensive loss was equal to the net loss amounts presented in the accompanying consolidated statements of operations. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of net revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include the estimates of fair values of assets acquired and liabilities assumed in business combinations, contractual allowances and bad debt reserves, the recoverability of long-lived assets, the valuation allowance relating to the Company’s deferred tax assets, the valuations of investments and related party receivables, equity and derivative instruments, income from HHS Provider Relief Funds and deemed dividends, litigation and related reserves, among others. Actual results could differ from those estimates and would impact future results of operations and cash flows. Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation and to present certain liabilities and other income in 2022 as part of discontinued operations. Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. Revenue Recognition We recognize revenue in accordance with Accounting Standard Codification (“ASC”), “ Revenue from Contracts with Customers (Topic 606),” Our revenues relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods averaging approximately three days, and revenues are recognized based on charges incurred. Our performance obligations for outpatient services, including emergency room-related services, are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare, because of the Big South Fork Medical Center’s designation as a Critical Access Hospital, generally pays for inpatient and outpatient services at rates related to the hospital’s costs. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Our net revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect. Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. Estimated reimbursement amounts are adjusted in subsequent periods as cost reports are prepared and filed and as final settlements are determined (in relation to certain government programs, primarily Medicare, this is generally referred to as the “cost report” filing and settlement process). As of December 31, 2023, $ 2.3 The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of operating cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed. The estimates for implicit price concessions are based upon management’s assessment of historical write offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable (the “hindsight analysis”) as a primary source of information in estimating the collectability of our accounts receivable. Contractual Allowances and Doubtful Accounts Policy Accounts receivable are reported at realizable value, net of estimated contractual allowances and estimated implicit price concessions (also referred to as doubtful accounts), which are estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimating and reviewing the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to contractual allowances and doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues that may impact the receivables or reserve estimates. Receivables deemed to be uncollectible are charged against the allowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts. Revisions to the allowances for doubtful accounts are recorded as an adjustment to revenues. During the years ended December 31, 2023 and 2022, estimated contractual allowances of $ 40.4 32.0 5.7 7.3 46.1 39.3 18.7 13.0 Impairment or Disposal of Long-Lived Assets We account for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board (the “FASB”) ASC Topic 360, Property, Plant and Equipment InnovaQor, Inc. Preferred Stock Investment We evaluate the carrying value of our preferred stock investment in InnovaQor, Inc. (“InnovaQor”) on an annual basis. To the extent, the Company believes an impairment in the investment might exist, a third-party valuation report is completed and the fair value of such investment is adjusted accordingly to the extent the valuation changed. Leases in Accordance with ASU No. 2016-02 We account for leases in accordance with ASU No. 2016-02, Leases (Topic 842) Fair Value Measurements In accordance with ASC 820, “ Fair Value Measurements and Disclosures ● Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date. ● Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; or quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets). ● Level 3 applies to assets or liabilities for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including our own assumptions. On December 31, 2023 and 2022, we applied the Level 3 fair value hierarchy in determining the fair value of InnovaQor’s Series B-1 Non-Voting Convertible Preferred Stock (the “InnovaQor Series B-1 Preferred Stock”), which is reflected on our consolidated balance sheets as an investment. During the year ended December 31, 2023, we recorded a charge of $ 0.8 Derivative Financial Instruments and Fair Value, Including ASU 2017-11 and ASU 2021-04 In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings (loss) per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common stockholders in basic and diluted EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10) 0.052 no 330.5 In addition, we recorded deemed dividends of approximately $ 0.3 Income Taxes Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized. When projected future taxable income is insufficient to provide for the realization of deferred tax assets, the Company recognizes a valuation allowance. In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability (or reducing a tax asset) that would reduce net assets. The Company did not have an unrecognized tax benefit at December 31, 2023 and 2022. Earnings (Loss) Per Share The Company reports earnings (loss) per share in accordance with ASC Topic 260, “Earnings Per Share,” which establishes standards for computing and presenting earnings (loss) per share. Basic earnings (loss) per share of common stock is calculated by dividing net earnings (loss) available to common stockholders by the weighted average shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted earnings (loss) per share is calculated by adjusting the weighted average shares of common stock outstanding for the dilutive effect of common stock equivalents, including preferred stock, convertible debt, stock options and warrants outstanding for the period, with options and warrants determined using the treasury stock method. For purposes of the diluted earnings (loss) per share calculation, common stock equivalents are excluded from the calculation when their effect would be anti-dilutive. See Note 3 for the computation of net loss per share for the years ended December 31, 2023 and 2022.

Loss per Share

Loss per Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Loss per Share	Note 3 – Loss per Share The loss per share accounting guidance is discussed in Note 2. Diluted loss per share excludes all dilutive potential shares if their effect is anti-dilutive. The following table sets forth the computation of the Company’s basic and diluted net loss per share available to common stockholders for the years ended December 31, 2023 and 2022: Schedule of Basic and Diluted Net Loss Per Share Available to Common Stockholders 2023 2022 Year Ended December 31, 2023 2022 Numerator Net loss from continuing operations, net of noncontrolling interest $ (534,085 ) $ (3,349,899 ) Deemed dividends - (330,876,369 ) Net loss available to common stockholders, continuing operations (534,085 ) (334,226,268 ) Net (loss) income from discontinued operations (7,195,076 ) 56,844 Net loss available to common stockholders $ (7,729,161 ) $ (334,169,424 ) Denominator Net loss per share of common stock available to common stockholders - basic: Continuing operations $ (0.00 ) $ (0.03 ) Discontinued operations (0.00 ) 0.00 Total basic and diluted $ (0.00 ) $ (0.03 ) Weighted average number of shares of common stock outstanding during the period – basic and diluted 32,825,519,517 9,992,238,468 Diluted loss per share excludes all dilutive potential shares if their effect is anti-dilutive. As of December 31, 2023 and 2022, the following potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 Year Ended December 31, 2023 2022 Common stock warrants 511,333,351,089 511,333,351,090 Convertible preferred stock 441,250,633,333 452,995,411,111 Convertible debentures 28,777,833,333 28,777,833,333 Stock options 26 26 Anti-dilutive shares 981,361,817,781 993,106,595,560 Subsequent to December 31, 2023, 2.5 101.3 101.3 The terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to floors in certain cases) in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. In addition, many of these securities contain exercise or conversion prices that vary based upon the price of the Company’s common stock on the date of exercise/conversion (see Notes 11 and 12). These provisions have resulted in significant dilution of the Company’s common stock. As a result of the Voting Agreement and Irrevocable Proxy (the “Voting Agreement”) discussed in Note 12 and the November 5, 2021 Amendment to the Company’s Certificate of Incorporation, as amended, to provide that the number of authorized shares of the Company’s common stock or preferred stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the Company, which is more fully discussed in Note 1, as of the date of filing this report, the Company believes that it has the ability to ensure that it has and/or can obtain sufficient authorized shares of its common stock to cover all outstanding rights to acquire potentially dilutive common shares. The potential common stock and common stock equivalents totaled 424.2

Accounts Receivable and Income

Accounts Receivable and Income Tax Refund Receivable	12 Months Ended
	Dec. 31, 2023
Receivables [Abstract]
Accounts Receivable and Income Tax Refund Receivable	Note 4 – Accounts Receivable and Income Tax Refund Receivable Accounts receivable at December 31, 2023 and 2022 consisted of the following: Schedule of Accounts Receivable December 31, 2023 December 31, Accounts receivable, gross $ 12,799,901 $ 13,046,646 Less: Allowance for contractual obligations (8,208,745 ) (8,529,904 ) Allowance for doubtful accounts (1,503,736 ) (1,405,773 ) Accounts receivable, net $ 3,087,420 $ 3,110,969 Income Tax Refund Receivable As of December 31, 2023 and 2022, the Company had $ 0.8 million and $ 0.8 million, respectively, of income tax refunds receivable. The Company’s income taxes are more fully discussed in Note 13.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Note 5 – Property and Equipment, Net Property and equipment, net at December 31, 2023 and 2022 consisted of the following: Schedule of Property and Equipment, Net December 31, 2023 December 31, Buildings $ 4,268,028 $ 4,181,434 Land 550,700 550,700 Equipment 1,746,412 1,637,585 Equipment under capital leases 189,711 189,711 Furniture 123,497 38,798 Leasehold improvements 151,790 2,160 Computer equipment 32,115 32,115 Software 7,775 402,815 Property and equipment, gross 7,070,028 7,035,318 Less accumulated depreciation (2,748,729 ) (2,841,019 ) Property and equipment, net $ 4,321,299 $ 4,194,299 Property and equipment are depreciated on a straight-line basis over their respective lives. Buildings are depreciated over 39 three seven years 0.3 0.5 Management periodically reviews the valuation of long-lived assets, including property and equipment, for potential impairment. The Company did not record an asset impairment charge during the years ended December 31, 2023 and 2022.

Intangible Asset

Intangible Asset	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Asset	Note 6 – Intangible Asset At December 31, 2023 and 2022, the Company had an intangible asset valued at $ 259,443

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses	Note 7 – Accrued Expenses Accrued expenses at December 31, 2023 and 2022 consisted of the following: Schedule of Accrued Expenses December 31, December 31, 2022 Accrued payroll and related liabilities $ 8,338,517 $ 8,433,076 HHS Provider Relief Funds 144,805 552,099 Accrued interest 6,663,561 5,732,306 Accrued legal expenses and settlements 1,797,170 534,550 Medicare cost report settlement reserves 2,264,847 2,101,837 Other accrued expenses 2,383,068 2,030,935 Total accrued expenses 21,591,968 19,384,803 Less current portion of accrued expenses (15,399,268 ) (19,384,803 ) Accrued expenses long-term $ 6,192,700 $ - Accrued payroll and related liabilities included approximately $ 7.3 7.0 As of December 31, 2023 and 2022, the Company has accrued approximately $ 0.1 0.6 As of December 31, 2023, accrued expenses long-term consisted of $ 6.2

Debt

Debt	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Debt	Note 8 – Debt At December 31, 2023 and 2022, debt consisted of the following: Schedule of Debt December 31, December 31, Notes payable- third parties $ 1,026,758 $ 2,917,390 Loan payable – related party 2,168,000 2,995,000 Debentures 8,222,240 8,622,240 Total debt 11,416,998 14,534,630 Less current portion of debt (3,194,758 ) (14,534,630 ) Total debt, net of current portion $ 8,222,240 $ - At December 31, 2023 and 2022, notes payable with third parties consisted of the following: Schedule of Notes Payable Third Parties Notes Payable – December 31, December 31, Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000 (the “Tegal Notes”). $ - $ 291,557 Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $ 500,000 $ - $ 291,557 Note payable to Anthony O’Killough dated September 27, 2019 in the original principal amount of $ 1.9 0.3 0.1 - 1,137,380 Notes payable to Western Healthcare, LLC dated August 10, 2021, in the aggregate principal amount of $ 2.4 18 0.2 1,026,758 1,488,453 Notes payable 1,026,758 2,917,390 Less current portion (1,026,758 ) (2,917,390 ) Notes payable - third parties, net of current portion $ - $ - On December 7, 2016, the holders of the Tegal Notes filed suit against the Company seeking payment for the amounts due under the notes and accrued interest. On April 23, 2018, the holders of the Tegal Notes received a judgment against the Company in the amount of $ 384,384 462,500 200,000 43,750 36,443 On September 27, 2019, the Company issued a promissory note payable to Anthony O’Killough in the principal amount of $ 1.9 2.2 450,000 750,000 300,000 350,000 1.1 580,000 0.6 On August 10, 2021, the Company entered into two notes payable to Western Healthcare, LLC in the aggregate principal amount of $ 2.4 18 0.2 400,000 200,000 0.2 Loan Payable – Related Party At December 31, 2023 and 2022, loan payable - related party consisted of the following: Schedule of Loan Payable Related Parties December 31, December 31, Loan payable to Christopher Diamantis $ 2,168,000 $ 2,995,000 Less current portion of loan payable, related party (2,168,000 ) (2,995,000 ) Total loan payable, related party, net of current portion $ — $ — Mr. Diamantis was a member of the Company’s Board of Directors until his resignation on February 26, 2020. During the years ended December 31, 2023 and 2022, Mr. Diamantis loaned the Company $ 0.6 1.1 Notes Payable –Third Parties 1.4 1.0 2.2 During the years ended December 31, 2023 and 2022, the Company incurred interest expense on the loans from Mr. Diamantis of $ 0.1 0.1 0.1 0.4 No 10 Debentures The carrying amount of all outstanding debentures as of December 31, 2023 and 2022 was as follows: Schedule of Debentures December 31, December 31, March 2017 Debenture $ 2,580,240 $ 2,580,240 2018 Debentures 5,642,000 5,642,000 October 2022 Debentures - 400,000 Debentures, Gross 8,222,240 8,622,240 Less current portion - (8,622,240 ) Debentures, net of current portion $ 8,222,240 $ - March 2017 Debenture In March 2017, the Company issued a debenture due in March 2019 (the “March 2017 Debenture”), which had a principal balance of $ 2.6 30 0.6 Debentures Amendment and Waiver Agreement. 18 0.3 0.5 On December 31, 2023, the March 2017 Debenture is convertible into shares of the Company’s common stock, at a conversion price, which has been adjusted pursuant to its terms, of $ 0.00009 28.7 The March 2017 Debenture was issued with common stock warrants (the “March Warrants”), which are more fully discussed in Notes 11, 12 and 18. 2018 Debentures During 2018, the Company closed various offerings of debentures (the “2018 Debentures”) with principal balances aggregating $ 14.5 30 1.3 5.6 Debentures Amendment and Waiver Agreement. 18 0.8 1.0 The conversion terms of the 2018 Debentures are the same as those of the March 2017 Debenture, as more fully described above, with the exception of the conversion price, which was $ 0.052 0.052 108.5 Debentures Amendment and Waiver Agreement On October 25, 2023, the Company entered into an Amendment and Waiver Agreement (the “Amendment Agreement”) with the holders of its March 2017 Debenture and 2018 Debentures. Under the Amendment Agreement, all defaults under these debentures were waived and the maturity dates of these debentures and the $ 6.2 8.2 6.2 October 2022 Debentures On October 12, 2022, the Company issued non-convertible debentures (the “October 2022 Debentures”) in the amount of $ 550,000 50,000 500,000 50,000 150,000 100,000 th During the years ended December 31, 2023 and 2022, the Company incurred interest expense on debentures totaling $ 1.1 1.5 50,000 6.2 5.1 See Notes 3 and 12 for a discussion of the dilutive effect of the outstanding convertible debentures and warrants as of December 31, 2023. During the year ended December 31, 2022, the Company recorded $ 330.5

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 9 – Related Party Transactions In addition to the transactions discussed in Notes 8, 11 and 12, the Company had the following related party activity during the years ended December 31, 2023 and 2022: Alcimede Limited Pursuant to a consulting agreement, Alcimede Limited billed $ 0.5 0.4 InnovaQor, Inc. In addition to the investment in InnovaQor’s Series B-1 Preferred Stock (see Note 11), at December 31, 2023 and 2022, the Company had a notes receivable resulting from working capital advances to InnovaQor of approximately $ 2.7 1.5 1.2 1.5 As of July 1, 2022, the Company had an outstanding related party receivable from InnovaQor of $ 803,416 883,757 10 883,757 441,018 1,457,253 10 132,478 June 30, 2023 25 18 0.2 June 30, 2023 to December 31, 2023 5 0.1 Effective December 31, 2023, the Company and InnovaQor agreed to restructure the promissory note receivable in favor of the Company in the amount of $ 1,530,116 and additional monies owed in the amount of $ 1,198,191 for a new promissory note receivable with a principal amount of $ 3,000,000 (inclusive of a 10 271,693 ) and a maturity date of December 31, 2024 except that InnovaQor will pay 25 % of any capital it receives from new capital secured prior to the maturity date. The note receivable, in the event of default, bears interest at 18 % per annum. The Company will recognize the original issue discount of $ 271,694 as interest income in 2024. During the years ended December 31, 2023 and 2022, the Company contracted with InnovaQor to provide ongoing health information technology-related services totaling approximately $ 0.4 0.2 10,400 Between January 1, 2024 and December 31, 2024, the Company advanced $ 0.3 Staff Accountant Loan During 2020, the Company’s staff accountant, Ms. Kristi Dymond, received approximately $ 82,500 The terms of the foregoing activities, and those discussed in Notes 8, 11 and 12 are not necessarily indicative of those that would have been agreed to with unrelated parties for similar transactions.

Operating Lease Obligations

Operating Lease Obligations	12 Months Ended
	Dec. 31, 2023
Operating Lease Obligations
Operating Lease Obligations	Note 10 – Operating Lease Obligations We lease property under operating leases. For operating leases with terms greater than 12 months, we record the related right-of-use assets and right-of-use obligations at the present value of lease payments over the term. We do not separate lease and non-lease components of contracts. Generally, we use our most recent agreed-upon borrowing interest rate at lease commencement as our interest rate, as most of our operating leases do not provide a readily determinable implicit interest rate. The following table presents our lease-related assets and liabilities at December 31, 2023 and 2022: Schedule of Lease-related Assets and Liabilities Balance Sheet Classification December 31, December 31, Assets: Total operating leases Right-of-use operating lease assets $ 359,194 $ 574,256 Liabilities: Current: Operating leases Right-of-use operating lease obligations $ 183,345 $ 215,063 Noncurrent: Operating leases Right-of-use operating lease obligations 175,849 359,193 Total lease liabilities $ 359,194 $ 574,256 Weighted-average remaining term: Operating leases 1.83 2.59 Weighted-average discount rate: Operating leases 13.0 % 13.0 % The following table presents certain information related to lease expense for operating leases for the years ended December 31, 2023 and 2022: Schedule of Lease Expense Year Ended Year Ended December 31, 2022 Operating leases: Short-term lease expense (1) $ 342,114 $ 323,506 Total lease expense $ 342,114 $ 323,506 (1) Expense is included in general and administrative expenses in the consolidated statements of operations. Other Information The following table presents supplemental cash flow information for the years ended December 31, 2023 and 2022: Schedule of Lease Supplemental Cash Flow Information Year Ended December 31, 2023 Year Ended December 31, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 265,307 $ 323,961 Aggregate future minimum lease payments under the right-of-use operating lease outstanding at December 31, 2023 are as follows: Schedule of Future Minimum Rentals Under Right-of-use Operating Leases Right-of-Use Twelve months ending December 31: 2024 $ 219,463 2025 186,496 2026 - 2027 - 2028 - Thereafter - Total 405,959 Less interest (46,765 ) Present value of minimum lease payments 359,194 Less current portion of operating lease obligation (183,345 ) Operating lease obligation, net of current portion $ 175,849

Fair Value, Derivative Financia

Fair Value, Derivative Financial Instruments and Deemed Dividends	12 Months Ended
	Dec. 31, 2023
Fair Value Derivative Financial Instruments And Deemed Dividends
Fair Value, Derivative Financial Instruments and Deemed Dividends	Note 11 – Fair Value, Derivative Financial Instruments and Deemed Dividends Fair Value Measurements The estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies considered to be appropriate. The fair value measurements accounting guidance is more fully discussed in Note 2. At December 31, 2023 and 2022, the carrying value of the Company’s accounts receivable, note receivable/receivable from related party, accounts payable and accrued expenses approximated their fair values due to their short-term nature. The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2023 and 2022: Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis Level 1 Level 2 Level 3 Total As of December 31, 2022: InnovaQor Series B-1 Preferred Stock $ - $ - $ 9,016,072 $ 9,016,072 Embedded conversion option of debenture - - 455,336 455,336 Total $ - $ - $ 9,471,408 $ 9,471,408 As of December 31, 2023: InnovaQor Series B-1 Preferred Stock $ - $ - $ 8,192,476 $ 8,192,476 Embedded conversion option of debenture - - 455,336 455,336 Total $ - $ - $ 8,647,812 $ 8,647,812 InnovaQor Series B-1 Preferred Stock During 2021, the Company sold several subsidiaries to InnovaQor. As consideration for the sale, the Company received 14,950 100 14,850 The fair value of the InnovaQor Series B-1 Preferred Stock was determined to be $ 8,192,476 9,016,072 823,596 3.84 215 5 45 0.84 250.0 5 35 In determining fair value, consideration was also given to: (i) the variable rate conversion feature of the InnovaQor Series B-1 Preferred Stock in that changes in the price of the common stock do not affect conversion value; (ii) recent sales and offering prices by InnovaQor of shares of its common stock; (iii) that InnovaQor is actively seeking additional capital; and (iv) other considerations that we believe will affect the underlying liquidity of InnovaQor’s common stock. Derivative Financial Instrument The Company utilized the following method to value its derivative liability as of December 31, 2023 and 2022 for an embedded conversion option related to an outstanding convertible debenture valued at $ 455,336 85% no no Deemed Dividends During the year ended December 31, 2023 there were no triggers of down round provisions of outstanding warrants and, therefore, no associated deemed dividends were recorded. During the year ended December 31, 2022, the conversions of preferred stock triggered a further reduction in the exercise prices of warrants containing down round provisions. In accordance with U.S. GAAP, the incremental fair value of the warrants as a result of the decreases in the exercise prices, was measured using Black Scholes valuation models. The following assumptions were utilized in the Black Scholes valuation models for the year ended December 31, 2022: risk free rates ranging from 0.0 2.73 1.94 1,564.0 0.01 2.45 330.5 As more fully discussed in Note 12, deemed dividends of $ 0.3

Stockholders_ Deficit

Stockholders’ Deficit	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Stockholders’ Deficit	Note 12 – Stockholders’ Deficit Authorized Capital The Company has 250,000,000,000 0.0001 5,000,000 0.01 Preferred Stock As of December 31, 2023, the Company had outstanding shares of preferred stock consisting of 10 250,000 20,810.35 2,403.78 8,149.59 10,194.87 Series F Preferred Stock On September 27, 2022, the Company’s then outstanding 17,500 174,097 Series H Preferred Stock Each of the 10 1,000 85% Series L Preferred Stock The Series L Preferred Stock is held by Alcimede LLC and has a stated value of $ 1.00 0.0001 Series M Preferred Stock On June 30, 2020, the Company and Mr. Diamantis entered into an exchange agreement wherein Mr. Diamantis agreed to the extinguishment of the Company’s indebtedness to him totaling $ 18.8 22,000 0.01 1,000 The terms of the Series M Preferred Stock include: (i) each share of the Series M Preferred Stock is convertible into shares of the Company’s common stock at a conversion price equal to 90% 10% provided however 51% 51% During the year ended December 31, 2021, Mr. Diamantis converted a total of 610.65 0.6 45 570 0.6 9,500 4,750 70.00 3.7 0.00009 20,810.35 208.1 Series N Preferred Stock The Company’s Board of Directors has designated 50,000 5,000,000 1,000 30,435.52 The terms of the Series N Preferred Stock include: (i) each share of the Series N Preferred Stock is convertible into shares of the Company’s common stock, at any time and from time to time, at the option of the holder, into that number of shares of common stock determined by dividing the stated value of such share of Series N Preferred Stock, plus any accrued declared and unpaid dividends, by the conversion price; (ii) the conversion price is equal to 90% 10% provided however During the years ended December 31, 2023 and 2022, the holders converted 496.53 3,035.57 0.5 3.0 5.5 16.0 2,403.78 26.7 Series O Preferred Stock On May 10, 2021, the Company closed an offering of shares of its Series O Preferred Stock. The offering was pursuant to the terms of the Securities Purchase Agreement, dated as of May 10, 2021 (the “Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Purchase Agreement provided for the issuance of up to 4,400 1,100 The Company entered into a second Securities Purchase Agreement (the “Second Purchase Agreement”), dated as of September 7, 2021, between the Company and certain existing institutional investors of the Company. The Second Purchase Agreement provided for the issuance of up to 1,100 550 On October 28, 2021, the Company entered into a third Securities Purchase Agreement, dated as of October 28, 2021 (the “Third Purchase Agreement”), among the Company and certain existing institutional investors of the Company. The Third Purchase Agreement provided for the issuance of up to 4,400 2,200 As a result, during the year ended December 31, 2021, the Company issued 9,900 9.0 1,000 The terms of the Series O Preferred Stock include: (i) each share of the Series O Preferred Stock is convertible into shares of the Company’s common stock, at any time and from time to time, at the option of the holder, into that number of shares of common stock determined by dividing the stated value of such share of Series O Preferred Stock, plus any accrued declared and unpaid dividends, by the conversion price; (ii) the conversion price is equal to 90% 10% provided however During the years ended December 31, 2023 and 2022, the holders converted 535.5 1,214.9 0.5 1.2 6.0 13.1 8,149.59 90.6 8,000 Series P Preferred Stock On November 7, 2021, the Company entered into Exchange and Amendment Agreements (the “November 2021 Exchange Agreements”) with certain institutional investors in the Company wherein the investors agreed to reduce their holdings of $ 1.1 4.5 1.5 8,544.87 1,000 Common Stock Warrants” On March 11, 2022, under the terms of a securities purchase agreement dated January 31, 2022, the Company issued to the institutional investors an additional 1,100 1.0 550 0.5 0.3 10% The terms of the Series P Preferred Stock include: (i) each share of the Series P Preferred Stock is convertible into shares of the Company’s common stock, at any time and from time to time, at the option of the holder, into that number of shares of common stock determined by dividing the stated value of such share of Series P Preferred Stock, plus any accrued declared and unpaid dividends, by the conversion price; (ii) the conversion price is equal to 90 10 provided however On December 31, 2023, 10,194.87 0.00009 113.3 The following table summarizes the activity in the Company’s various classes of preferred stock included in Stockholders’ Deficit for the years ended December 31, 2023 and 2022: Schedule of Stockholders’ Deficit Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Series H Series L Series M Series N Series O Series P Total Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Balance December 31, 2022 10 $ - - 250,000 $ 2,500 20,810 $ 208 2,900 $ 29 8,685 $ 87 10,195 $ 102 292,600 $ 2,926 Conversion of Series F Preferred Stock into common stock - - - - - - - - - - - Conversion of Series F Preferred Stock into common stock, Shares - - - - - - - - - - - Issuances of Series P Preferred Stock - - - - - - - - - Issuances of Series P Preferred Stock, Shares - - - - - - - - - Conversions of Series N Preferred Stock into common stock - - - - - (496 ) (5 ) - - - - (496 ) (5 ) Conversions of Series O Preferred Stock into common stock - - - - - - - - (535 ) (5 ) - - (535 ) (5 ) Balance December 31, 2023 10 $ - - 250,000 $ 2,500 20,810 $ 208 2,404 $ 24 8,150 $ 82 10,195 $ 102 291,569 $ 2,916 Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Series H Series F Series L Series M Series N Series O Series P Total Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Balance December 31, 2021 10 $ - 1,750,000 $ 17,500 250,000 $ 2,500 20,810 $ 208 5,936 $ 59 9,900 $ 99 8,545 $ 85 2,045,201 $ 20,451 Balance 10 $ - 1,750,000 $ 17,500 250,000 $ 2,500 20,810 $ 208 5,936 $ 59 9,900 $ 99 8,545 $ 85 2,045,201 $ 20,451 Conversion of Series F Preferred Stock into common stock - - (1,750,000 ) (17,500 ) - - - - - - - - - (1,750,000 ) (17,500 ) Issuances of Series P Preferred Stock - - - - - - - - - - - - 1,650 17 1,650 17 Conversions of Series N Preferred Stock into common stock - - - - - - - (3,036 ) (30 ) - - - - (3,036 ) (30 ) Conversions of Series O Preferred Stock into common stock - - - - - - - - - - (1,215 ) (12 ) - - (1,215 ) (12 ) Balance December 31, 2022 10 $ - - $ - 250,000 $ 2,500 20,810 $ 208 2,900 $ 29 8,685 $ 87 10,195 $ 102 292,600 $ 2,926 Balance 10 $ - - $ - 250,000 $ 2,500 20,810 $ 208 2,900 $ 29 8,685 $ 87 10,195 $ 102 292,600 $ 2,926 Common Stock The Company had 40.6 29.1 5.5 496 6.0 535 1,750,000 16.0 3,036 13.1 1,215 The Company has outstanding options, warrants, convertible preferred stock and convertible debentures. Exercise of the outstanding options and warrants, and conversions of the convertible preferred stock and debentures could result in substantial dilution of the Company’s common stock and a decline in the market price of the common stock. In addition, the terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in certain cases), in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. These provisions, as well as the issuances of debentures and preferred stock with conversion prices that vary based upon the price of our common stock on the date of conversion, have resulted in significant dilution of the Company’s common stock and have given rise to reverse splits of its common stock, including the Reverse Stock Split, which is more fully discussed in Note 1. On August 13, 2020, Mr. Diamantis entered into the Voting Agreement with the Company, Mr. Lagan and Alcimede LLC (of which Mr. Lagan is the sole manager) pursuant to which Mr. Diamantis granted an irrevocable proxy to Mr. Lagan to vote the Series M Preferred Stock held by Mr. Diamantis. Mr. Diamantis has retained all other rights under the Series M Preferred Stock. Regardless of the number of shares of Series M Preferred Stock outstanding and so long as at least one share of Series M Preferred Stock is outstanding, the outstanding shares of Series M Preferred Stock shall have the number of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting of stockholders or action by written consent. This means that the holders of Series M Preferred Stock have sufficient votes, by themselves, to approve or defeat any proposal voted on by the Company’s stockholders, unless there is a supermajority required under applicable law or by agreement. As a result of the Voting Agreement discussed above and the November 5, 2021 Amendment to the Company’s Certificate of Incorporation, as amended, to provide that the number of authorized shares of the Company’s common stock or preferred stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the Company, which is more fully discussed in Note 1, as of the date of filing this report, the Company believes that it has the ability to ensure that it has and/or can obtain sufficient authorized shares of its common stock to cover all outstanding rights to acquire potentially dilutive common shares. Stock Options The Company maintained and sponsored the Tegal Corporation 2007 Incentive Award Equity Plan (the “2007 Equity Plan”). Tegal Corporation is the prior name of the Company. The 2007 Equity Plan, as amended, provided for the issuance of stock options and other equity awards to the Company’s officers, directors, employees and consultants. The 2007 Equity Plan terminated in September 2017. The following table summarizes the stock option activity for the years ended December 31, 2023 and 2022: Schedule of Stock Option Activity Number of options Weighted- average exercise price Weighted- average contractual term (years) Outstanding at December 31, 2021 26 $ 2,992,125 4.33 Granted - Expired - Outstanding at December 31, 2022 26 $ 2,992,125 3.37 Granted - Expired - Outstanding at December 31, 2023 26 $ 2,992,125 2.37 Exercisable at December 31, 2023 26 $ 2,992,125 As of December 31, 2023, the weighted average remaining contractual life was 2.37 0 The following table summarizes information with respect to stock options outstanding and exercisable by employees and directors at December 31, 2023: Schedule of Stock Option Outstanding and Exercisable Options outstanding Options vested and exercisable Exercise price Number outstanding Weighted average remaining contractual life (years) Weighted average exercise price Aggregate intrinsic value Number vested Weighted average exercise price Aggregate intrinsic value $ 10,000,000 5 2.25 $ 10,000,000 $ - 5 $ 10,000,000 $ - $ 5,000,000 5 2.25 $ 5,000,000 - 5 $ 5,000,000 - $ 269,580 8 2.33 $ 269,580 - 8 $ 269,580 - $ 80,906 8 2.54 $ 80,906 - 8 $ 80,906 - 26 2.37 $ 2,992,125 $ – 26 $ 2,992,125 $ - Common Stock Warrants The Company, as part of various debt and equity financing transactions, has issued warrants to purchase shares of the Company’s common stock exercisable into a total of 511.3 511.3 Included in the warrants outstanding at December 31, 2023 were the March Warrants issued in connection with the March 2017 Debentures. The Company issued these warrants to purchase shares of the Company’s common stock to several accredited investors. At December 31, 2023, these warrants were exercisable into an aggregate of approximately 507.6 190.0 127.6 190.0 five years March 21, 2024 0.00009 Subsequent to December 31, 2023 and through December 31, 2024, 2.5 508.8 101.3 Deemed Dividends During the year ended December 31, 2022, reductions in the exercise prices of the March Warrants gave rise to deemed dividends. See Note 11 for the assumptions used in the calculations of these deemed dividends. Deemed dividends are also discussed under the heading “Preferred Stock” above and in Notes 2, 3 and 11. Shares of Common Stock Issuable Under Warrants The number of shares of common stock issuable under warrants issued and outstanding as well as the exercise prices of the warrants reflected in the table below have been adjusted to reflect the full ratchet and other dilutive and down round provisions pursuant to the warrant agreements. As a result of the full down round provisions of the outstanding warrants (subject to a floor in some cases), subsequent issuances of the Company’s common stock or common stock equivalents at prices below the then current exercise prices of the warrants have resulted in increases in the number of shares issuable pursuant to the warrants and decreases in the exercise prices of the warrants. The following summarizes the information related to the number of shares of common stock issuable under outstanding warrants during the years ended December 31, 2023 and 2022: Schedule of Warrants Activity Number of Shares of Common Stock Issuable Warrants Weighted average exercise Balance at December 31, 2021 54,280,658 $ 1.43 Issuance of warrants - - Increase in number of shares of common stock issuable under 511,312,671,643 - Expiration of warrants (33,601,211 ) (0.9141 ) Balance at December 31, 2022 511,333,351,090 $ 0.00009 Issuance of warrants - - Expiration of warrants (1 ) (794,998 ) Balance at December 31, 2023 511,333,351,089 $ 0.00009 See above and Notes 2, 3 and 11 for a discussion of the dilutive effect on the Company’s common stock as a result of the outstanding warrants.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 13 – Income Taxes The provision for income taxes for the years ended December 31, 2023 and 2022 consists of the following: Schedule of Income Tax (Expense) Benefit Year Ended December 31, Year Ended December 31, Current Federal $ - $ (301,766 ) State (239,834 ) (11,083 ) Total Current (239,834 ) (312,849 ) Deferred Federal - - State - - Total Deferred - - Provision for income taxes $ (239,834 ) $ (312,849 ) The following reconciles the Federal statutory income tax rate to the Company’s effective tax rate for the years ended December 31, 2023 and 2022: Schedule of Effective Income Tax Rate Reconciliation Year Ended December 31, Year Ended December 31, % % Federal statutory rate 21.0 % 21.0 % Permanent and other items 15.0 (17.0 ) Federal income taxes audit and other adjustments - - Change in valuation allowance (39.2 ) (14.5 ) Effective income tax rate (3.2) % (10.5 )% Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. In assessing the realizability of deferred tax assets, management evaluates whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on Management’s evaluation, it is more likely than not that the deferred tax asset will not be realized and as such a valuation allowance has been recorded as of December 31, 2023 and 2022. Deferred tax assets and liabilities are comprised of the following at December 31, 2023 and 2022: Schedule of Deferred Tax Assets and Liabilities December 31, December 31, Deferred income tax assets: Amortization $ 233,410 $ 375,821 Net operating loss carryforward 17,668,228 15,445,916 Allowance for doubtful accounts 393,001 387,818 Charitable contributions - 644 Stock options - 1,003,453 Accrued liabilities 5,121,508 1,826,839 HHS Provider Relief Funds 37,845 67,685 Employee retention credit - 292,282 HTS and AMSG basis difference - 878,709 Deferred state tax asset 4,043,616 4,089,682 Total deferred income tax assets 27,497,608 24,368,849 Deferred income tax liabilities: Right-of-use asset (93,875 ) - Depreciation (670,176 ) (583,812 ) Deferred tax asset, net 26,733,557 23,785,037 Less: valuation allowance (26,733,557 ) (23,785,037 ) Net deferred tax assets $ - $ - Management has reviewed the provisions regarding assessment of its valuation allowance on deferred tax assets and based on that criteria determined that it should record a valuation allowance of $ 26.7 million and $ 23.8 million against its net deferred tax assets as of December 31, 2023 and 2022, respectively. The Company has federal net operating loss carryforwards totaling approximately $ 84.1 begin to expire in 2033 . The Company believes that a Section 382 limitation may exist for a portion of its net operating losses but at this time has not identified to which losses these limitations would relate. At December 31, 2023, the Company had federal income tax receivables of $ 0.8 million and federal tax liabilities of $ 0.7 0.9 The Company recognizes the consolidated financial statement impact of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than–not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood The Company is subject to income taxes in the U.S. federal jurisdiction and Tennessee. The tax regulations within each jurisdiction are subject to interpretation of related tax laws and regulations and require significant judgment to apply.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14 – Commitments and Contingencies Concentration of Credit Risk Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base. The Company does have significant receivable balances with government payers and various insurance carriers. Generally, the Company does not require collateral or other security to support customer receivables. However, the Company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable and establishes an allowance for uncollectible accounts and as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements. A number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid reimbursements to providers. Depending upon the nature of regulatory action, and the content of legislation, the Company could experience a significant decrease in net revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken. The Company maintains its cash balances in high credit quality financial institutions. The Company’s cash balances may, at times, exceed the deposit insurance limits provided by the Federal Deposit Insurance Corp. Legal Matters From time to time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company’s financial position or results of operations. The Company’s policy is to expense legal fees and expenses incurred in connection with the legal proceedings in the period in which the expense is incurred. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below. Biohealth Medical Laboratory, Inc. and PB Laboratories, LLC (the “Companies”), subsidiaries of Rennova, filed suit against CIGNA Health in 2015 alleging that CIGNA failed to pay claims for laboratory services the Companies provided to patients pursuant to CIGNA-issued and CIGNA-administered plans. In 2016, the U.S. District Court dismissed part of the Companies’ claims for lack of standing. The Companies appealed that decision to the Eleventh Circuit Court of Appeals, which in late 2017 reversed the District Court’s decision and found that the Companies have standing to raise claims arising out of traditional insurance plans, as well as self-funded plans. In July 2019, the Companies and EPIC filed suit against CIGNA Health for failure to pay claims for laboratory services provided. Cigna Health, in turn, sued for alleged improper billing practices. Because the Company did not have the financial resources to see the legal action to conclusion it assigned the benefit, if any, from the suit to Chris Diamantis, a former member of Rennova’s Board of Directors, for his financial support to the Company and assumption of all costs to carry the case to conclusion. On November 4, 2024, a jury in the United States District Court for the District of Connecticut awarded no amounts to the Companies and EPIC in connection with the lawsuit and an aggregate of $ 7.3 On September 27, 2016, a tax warrant was issued against the Company by the Florida Department of Revenue (the “DOR”) for unpaid 2014 state income taxes in the approximate amount of $ 0.9 million, including penalties and interest. The Company entered into a Stipulation Agreement with the DOR allowing the Company to make monthly installments until July 2019. The Company made payments to reduce the amount owed but did not discharge the liability in full. In March 2024, the Company entered into a Stipulation Agreement with the DOR. Under the terms of the agreement, the Company agreed to pay $ 645,909 in 11 monthly payments of $ 15,000 beginning in March 2024 with a final payment of $ 480,909 due on February 18, 2025. The Company has not made the required payments to discharge this liability and has accrued $0.6 million for this liability as of December 31, 2023. On December 7, 2016, the holders of the Tegal Notes filed suit against the Company seeking payment for the amounts due under the notes and accrued interest. On April 23, 2018, the holders of the Tegal Notes received a judgment against the Company in the amount of $ 384,384 462,500 200,000 43,750 In July 2019, CHSPSC, the former owners of Jamestown Regional Medical Center, obtained judgments against the Company of $ 1.3 Company agreed to make periodic payments totaling $ 705,000 100,000 15,000 85,000 55,000 A sealed qui tam 253,000 164,000 1,200,000

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Note 15 – Discontinued Operations EPIC Reference Labs, Inc. and Other Non-Operating Subsidiaries During the third quarter of 2020, the Company made a decision to sell EPIC and to discontinue several other non-operating subsidiaries. During the fourth quarter of 2024, the Company discontinued several additional non-operating subsidiaries. As a result, EPIC’s and the other non-operating subsidiaries’ liabilities have been included in discontinued operations for all periods presented. The Company was unable to find a buyer for EPIC and, therefore, it has ceased all efforts to sell EPIC and closed down its operations. Carrying amounts of major classes of liabilities of EPIC and the other non-operating subsidiaries included as part of discontinued operations in the consolidated balance sheets as of December 31, 2023 and 2022 consisted of the following: Schedule of Discontinued Operation of Unaudited Balance Sheet and Operation Statement December 31, December 31, 2022 Accounts payable $ 1,425,083 $ 1,425,083 Accrued expenses (1) 7,666,630 520,051 Finance lease obligation (2) 220,461 220,461 Current liabilities of discontinued operations $ 9,312,174 $ 2,165,595 (1) Included in accrued expenses at December 31, 2023 was $ 7.3 (2) As of December 31, 2023 and 2022, the Company was in default under the finance lease obligation. Therefore, the aggregate future minimum lease payments under this finance lease totaling $ 0.2 Line items constituting (loss) income from discontinued operations in the consolidated statements of operations for the years ended December 31, 2023 and 2022 consisted of the following: Consolidated (Loss) Income from Discontinued Operations: 2023 2022 Year Ended December 31, 2023 2022 Other (expense) income, net (1) $ (7,195,076 ) $ 56,844 Provision for income taxes - - (Loss) income from discontinued operations $ (7,195,076 ) $ 56,844 (1) Included in other expense for the year ended December 31, 2023 was $ 7.3

Supplemental Disclosure of Cash

Supplemental Disclosure of Cash Flow Information	12 Months Ended
	Dec. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	Note 16 – Supplemental Disclosure of Cash Flow Information Schedule of Supplemental Cash Flow Information 2023 2022 Year Ended December 31, 2023 2022 Cash paid for interest $ 419,177 $ 1,545,839 Cash paid for income taxes $ - $ - Non-cash investing and financing activities: Series F Preferred Stock converted into common stock $ - $ 17,500 Stated value of Series N Preferred Stock converted into common stock 496,530 3,035,570 Stated value of Series O Preferred Stock converted into common stock 535,500 1,214,910 Deemed dividends from issuances of Series P Preferred Stock - 333,333 Deemed dividends from down-round provisions of warrants - 330,543,036 Non-cash interest income 90,653 212,819 Original issue discounts on debt - 50,000

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2023
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	Note 17 – Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820) Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Topic 820, Fair Value Measurement Topic 820 In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures In November 2024, the FASB issued ASU 2024-04, Debt with Conversions and Other Options (Subtopic Induced Conversions of Convertible Debt Instruments. Other recent accounting standards issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 18 – Subsequent Events CarePlus Clinic Closure On January 31, 2024, the Company closed its CarePlus Clinic (located in Williamsburg, Kentucky) due to the loss of the clinic’s clinicians and other factors. Legal Settlements/Stipulation As discussed in Note 14, in July 2019, CHSPSC obtained judgments against the Company of $ 1.3 Company agreed to make periodic payments totaling $ 705,000 100,000 15,000 85,000 55,000 As discussed in Note 14, in March 2024, the Company entered into a Stipulation Agreement with the DOR. Under the terms of the agreement, the Company agreed to pay $ 645,909 15,000 480,909 Exercise of Series B Warrants and Extension of Series B Warrants Exercise Period Subsequent to December 31, 2023, 2.5 0.00009 101.3 Schedule of Warrants From March 21, 2024 to April 15, 2024 1,350,000,000 From April 16, 2024 to August 30, 2024 2,500,000,000 From August 31, 2024 to December 27, 2024 4,000,000,000 From December 28, 2024 to April 24, 2025 4,000,000,000 From April 25, 2025 to August 29, 2025 4,000,000,000 Such share numbers are subject to adjustment in the case of stock splits, combinations, dividends, reclassifications, recapitalizations or other similar events. No cashless exercise of Series B Warrants shall count toward the satisfaction of an Exercise Condition. Other than the Series B Warrants to acquire 101.3 190 23.8 190 101.3 Promissory Note with Institutional Investor On October 25, 2024, the Company issued a promissory note to an institutional investor in the principal amount of $ 460,000 15 60,000 50 350 Accounts Receivable Sales Agreements During the period January 1, 2024 to September 10, 2024, SCCH entered into four accounts receivable sales agreements whereby portions of SCCH’s accounts receivable were sold for net proceeds of $ 1.1 1.8 0.7 0.5 Stock Exchange Agreements On June 10, 2024, the Company entered into two stock exchange agreements, each with FOXO Technologies, Inc. (“FOXO”). Sale of Myrtle Under First Stock Exchange Agreement The first agreement with FOXO, dated June 10, 2024, (the “Myrtle Agreement”), provided for the Company to exchange all of its equity interest in Myrtle for $ 0.5 1,023,629 0.2 0.3 In addition to the $ 0.3 1.6 December 31, 2024 18 Sale of Rennova Community Health, Inc. (“RCHI”) Under Second Stock Exchange Agreement The second agreement with FOXO, also dated June 10, 2024, (the “RCHI Agreement”) provided for the Company to exchange all of the outstanding shares of its subsidiary RCHI, including RCHI’s wholly-owned subsidiary Scott County Community Hospital, Inc. (“SCCH”), for 20,000 100 22.0 The RCHI Note matured on September 10, 2026 The RCHI Note was guaranteed by FOXO and SCCH, pursuant to the terms of a Guaranty Agreement (the “Guaranty”). The RCHI Note was also secured by the assets of RCHI and Scott County pursuant to a Security and Pledge Agreement (the “RCHI Pledge Agreement”) and by the “Collateral” owned by FOXO as provided in the Security and Pledge Agreement with FOXO (the “FOXO Pledge Agreement”). The Amendment also provides that the Company may at any time request that FOXO seek approval of its shareholders of the issuance of FOXO Common Stock upon conversion in full of the shares of FOXO Series A Preferred Stock issuable upon exchange of the RCHI Note. At any time after receipt of such approval, the Company shall have the option to exchange, in whole or in part, the RCHI Note for shares of FOXO Series A Preferred Stock. Upon any such exchange, the Company will receive the equivalent of $ 1.00 1.00 21.0 21,000 1.0 June 5, 2025 In connection with the Myrtle Agreement and the RCHI Agreement and required consents for the transactions, the Company agreed to an exchange right whereby institutional investors owning the Company’s preferred stock may exchange up to $ 8 8 8 Unaudited Pro Forma Balance Sheet Data and Results of Operations Data of the Company Reflecting the Dispositions of Myrtle and RCHI The following presents the unaudited pro forma balance sheet data as if the dispositions of Myrtle and RCHI had occurred on December 31, 2023. The unaudited pro forma balance sheet data are presented for information purposes only and are not intended to present the actual balance sheet that would have occurred had the dispositions been completed on December 31, 2023. The unaudited pro forma balance sheet data does not include any income tax effect that may result from the dispositions. Schedule of Pro-forma Balance Sheet Data Unaudited Pro Forma Balance Sheet Data December 31, 2023 Assets Related party notes receivable $ 5,603,543 Other current assets 875,216 Property and equipment, net 3,870,037 Investments in related parties 29,427,911 Other long-teem assets 739,647 Total assets $ 40,516,354 Liabilities and stockholders’ deficit Account payable and accrued expenses $ 19,155,690 Debt (includes related party loan of $2.2 million) 2,570,926 Other current liabilities 638,681 Current liabilities of discontinued operations 9,312,174 Long-term debt 8,222,240 Other long-term liabilities 6,368,549 Total liabilities 46,268,260 Stockholders’ deficit (5,751,906 ) Total liabilities and stockholders’ deficit $ 40,516,354 The following presents the unaudited pro forma results of operations data of the Company as if the dispositions of Myrtle and RCHI had occurred on January 1, 2022. The unaudited pro forma results of operations data are presented for information purposes only. The unaudited pro forma results of operations data are not intended to present actual results that would have occurred had the dispositions been completed as of January 1, 2022, or to project potential operating results as of any future date or for any future periods. The unaudited pro forma results of operations data do not include any gain or income tax effects that may result from the dispositions. Schedule of Unaudited Pro forma Dispositions 2023 2022 Unaudited Pro Forma Results of Operations Data Year Ended December 31, 2023 2022 Total revenue $ 1,274,718 $ 1,529,651 Net loss from continuing operations (4,639,798 ) (4,697,805 ) Deemed dividends - (330,876,369 ) Net loss from continuing operations available to common stockholders $ (4,639,798 ) $ (335,574,174 ) Net loss per common share: Basic and diluted net loss from continuing operation available to common stockholders $ (0.00 ) $ (0.03 ) Lease Agreements With Myrtle and SCCH The buildings and campus where the Big South Fork Medical Center is located were transferred to a subsidiary of the Company during the year ended December 31, 2023. Both Myrtle and SCCH lease the facilities at the Big South Fork campus per the terms of lease agreements discussed below. Myrtle entered into a lease agreement with the Company under which Myrtle agreed to lease facilities at Big South Fork’s campus beginning on June 14, 2024, the date that Myrtle was sold to FOXO. The lease is for a term of one year with five annual options to renew for an additional year with an initial monthly base rental amount of $ 35,000 3 On June 1, 2024, SCCH entered into a “triple net” lease agreement with the Company under which SCCH agreed to lease the Big South Fork’s hospital facilities. The lease is for a term of one year with five annual options to renew for an additional year with an initial monthly base rental amount of $ 65,000 3 Appointments to FOXO’s Management and Board of Directors Effective on September 10, 2024, Mr. Seamus Lagan, the Company’s Chief Executive Officer and member of its board of directors, and Trevor Langley, a member of the Company’s board of directors, were appointed to the board of directors of FOXO. In addition, effective on December 5, 2024, Mr. Lagan was appointed Chief Executive Officer of FOXO. New Corporate Office Lease Agreement During February 2025, the Company terminated its existing corporate office lease and it leased space in a new office building for a term of three years.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and in accordance with Regulation S-X of the SEC. The consolidated financial statements include the accounts of Rennova Health, Inc. and its wholly-owned and majority-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
Comprehensive Loss	Comprehensive Loss During the years ended December 31, 2023 and 2022, comprehensive loss was equal to the net loss amounts presented in the accompanying consolidated statements of operations.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of net revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include the estimates of fair values of assets acquired and liabilities assumed in business combinations, contractual allowances and bad debt reserves, the recoverability of long-lived assets, the valuation allowance relating to the Company’s deferred tax assets, the valuations of investments and related party receivables, equity and derivative instruments, income from HHS Provider Relief Funds and deemed dividends, litigation and related reserves, among others. Actual results could differ from those estimates and would impact future results of operations and cash flows.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation and to present certain liabilities and other income in 2022 as part of discontinued operations.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents.
Revenue Recognition	Revenue Recognition We recognize revenue in accordance with Accounting Standard Codification (“ASC”), “ Revenue from Contracts with Customers (Topic 606),” Our revenues relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods averaging approximately three days, and revenues are recognized based on charges incurred. Our performance obligations for outpatient services, including emergency room-related services, are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare, because of the Big South Fork Medical Center’s designation as a Critical Access Hospital, generally pays for inpatient and outpatient services at rates related to the hospital’s costs. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Our net revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect. Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. Estimated reimbursement amounts are adjusted in subsequent periods as cost reports are prepared and filed and as final settlements are determined (in relation to certain government programs, primarily Medicare, this is generally referred to as the “cost report” filing and settlement process). As of December 31, 2023, $ 2.3 The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of operating cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed. The estimates for implicit price concessions are based upon management’s assessment of historical write offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable (the “hindsight analysis”) as a primary source of information in estimating the collectability of our accounts receivable.
Contractual Allowances and Doubtful Accounts Policy	Contractual Allowances and Doubtful Accounts Policy Accounts receivable are reported at realizable value, net of estimated contractual allowances and estimated implicit price concessions (also referred to as doubtful accounts), which are estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimating and reviewing the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to contractual allowances and doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues that may impact the receivables or reserve estimates. Receivables deemed to be uncollectible are charged against the allowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts. Revisions to the allowances for doubtful accounts are recorded as an adjustment to revenues. During the years ended December 31, 2023 and 2022, estimated contractual allowances of $ 40.4 32.0 5.7 7.3 46.1 39.3 18.7 13.0
Impairment or Disposal of Long-Lived Assets	Impairment or Disposal of Long-Lived Assets We account for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board (the “FASB”) ASC Topic 360, Property, Plant and Equipment
InnovaQor, Inc. Preferred Stock Investment	InnovaQor, Inc. Preferred Stock Investment We evaluate the carrying value of our preferred stock investment in InnovaQor, Inc. (“InnovaQor”) on an annual basis. To the extent, the Company believes an impairment in the investment might exist, a third-party valuation report is completed and the fair value of such investment is adjusted accordingly to the extent the valuation changed.
Leases in Accordance with ASU No. 2016-02	Leases in Accordance with ASU No. 2016-02 We account for leases in accordance with ASU No. 2016-02, Leases (Topic 842)
Fair Value Measurements	Fair Value Measurements In accordance with ASC 820, “ Fair Value Measurements and Disclosures ● Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date. ● Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; or quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets). ● Level 3 applies to assets or liabilities for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including our own assumptions. On December 31, 2023 and 2022, we applied the Level 3 fair value hierarchy in determining the fair value of InnovaQor’s Series B-1 Non-Voting Convertible Preferred Stock (the “InnovaQor Series B-1 Preferred Stock”), which is reflected on our consolidated balance sheets as an investment. During the year ended December 31, 2023, we recorded a charge of $ 0.8
Derivative Financial Instruments and Fair Value, Including ASU 2017-11 and ASU 2021-04	Derivative Financial Instruments and Fair Value, Including ASU 2017-11 and ASU 2021-04 In July 2017, the FASB issued ASU 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings (loss) per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common stockholders in basic and diluted EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10) 0.052 no 330.5 In addition, we recorded deemed dividends of approximately $ 0.3
Income Taxes	Income Taxes Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized. When projected future taxable income is insufficient to provide for the realization of deferred tax assets, the Company recognizes a valuation allowance. In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability (or reducing a tax asset) that would reduce net assets. The Company did not have an unrecognized tax benefit at December 31, 2023 and 2022.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company reports earnings (loss) per share in accordance with ASC Topic 260, “Earnings Per Share,” which establishes standards for computing and presenting earnings (loss) per share. Basic earnings (loss) per share of common stock is calculated by dividing net earnings (loss) available to common stockholders by the weighted average shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted earnings (loss) per share is calculated by adjusting the weighted average shares of common stock outstanding for the dilutive effect of common stock equivalents, including preferred stock, convertible debt, stock options and warrants outstanding for the period, with options and warrants determined using the treasury stock method. For purposes of the diluted earnings (loss) per share calculation, common stock equivalents are excluded from the calculation when their effect would be anti-dilutive. See Note 3 for the computation of net loss per share for the years ended December 31, 2023 and 2022.

Loss per Share (Tables)

Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share Available to Common Stockholders	The following table sets forth the computation of the Company’s basic and diluted net loss per share available to common stockholders for the years ended December 31, 2023 and 2022: Schedule of Basic and Diluted Net Loss Per Share Available to Common Stockholders 2023 2022 Year Ended December 31, 2023 2022 Numerator Net loss from continuing operations, net of noncontrolling interest $ (534,085 ) $ (3,349,899 ) Deemed dividends - (330,876,369 ) Net loss available to common stockholders, continuing operations (534,085 ) (334,226,268 ) Net (loss) income from discontinued operations (7,195,076 ) 56,844 Net loss available to common stockholders $ (7,729,161 ) $ (334,169,424 ) Denominator Net loss per share of common stock available to common stockholders - basic: Continuing operations $ (0.00 ) $ (0.03 ) Discontinued operations (0.00 ) 0.00 Total basic and diluted $ (0.00 ) $ (0.03 ) Weighted average number of shares of common stock outstanding during the period – basic and diluted 32,825,519,517 9,992,238,468
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2023 2022 Year Ended December 31, 2023 2022 Common stock warrants 511,333,351,089 511,333,351,090 Convertible preferred stock 441,250,633,333 452,995,411,111 Convertible debentures 28,777,833,333 28,777,833,333 Stock options 26 26 Anti-dilutive shares 981,361,817,781 993,106,595,560

Accounts Receivable and Incom_2

Accounts Receivable and Income Tax Refund Receivable (Tables)	12 Months Ended
	Dec. 31, 2023
Receivables [Abstract]
Schedule of Accounts Receivable	Accounts receivable at December 31, 2023 and 2022 consisted of the following: Schedule of Accounts Receivable December 31, 2023 December 31, Accounts receivable, gross $ 12,799,901 $ 13,046,646 Less: Allowance for contractual obligations (8,208,745 ) (8,529,904 ) Allowance for doubtful accounts (1,503,736 ) (1,405,773 ) Accounts receivable, net $ 3,087,420 $ 3,110,969

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net at December 31, 2023 and 2022 consisted of the following: Schedule of Property and Equipment, Net December 31, 2023 December 31, Buildings $ 4,268,028 $ 4,181,434 Land 550,700 550,700 Equipment 1,746,412 1,637,585 Equipment under capital leases 189,711 189,711 Furniture 123,497 38,798 Leasehold improvements 151,790 2,160 Computer equipment 32,115 32,115 Software 7,775 402,815 Property and equipment, gross 7,070,028 7,035,318 Less accumulated depreciation (2,748,729 ) (2,841,019 ) Property and equipment, net $ 4,321,299 $ 4,194,299

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses at December 31, 2023 and 2022 consisted of the following: Schedule of Accrued Expenses December 31, December 31, 2022 Accrued payroll and related liabilities $ 8,338,517 $ 8,433,076 HHS Provider Relief Funds 144,805 552,099 Accrued interest 6,663,561 5,732,306 Accrued legal expenses and settlements 1,797,170 534,550 Medicare cost report settlement reserves 2,264,847 2,101,837 Other accrued expenses 2,383,068 2,030,935 Total accrued expenses 21,591,968 19,384,803 Less current portion of accrued expenses (15,399,268 ) (19,384,803 ) Accrued expenses long-term $ 6,192,700 $ -

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Debt	At December 31, 2023 and 2022, debt consisted of the following: Schedule of Debt December 31, December 31, Notes payable- third parties $ 1,026,758 $ 2,917,390 Loan payable – related party 2,168,000 2,995,000 Debentures 8,222,240 8,622,240 Total debt 11,416,998 14,534,630 Less current portion of debt (3,194,758 ) (14,534,630 ) Total debt, net of current portion $ 8,222,240 $ -
Schedule of Notes Payable Third Parties	At December 31, 2023 and 2022, notes payable with third parties consisted of the following: Schedule of Notes Payable Third Parties Notes Payable – December 31, December 31, Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000 (the “Tegal Notes”). $ - $ 291,557 Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $ 500,000 $ - $ 291,557 Note payable to Anthony O’Killough dated September 27, 2019 in the original principal amount of $ 1.9 0.3 0.1 - 1,137,380 Notes payable to Western Healthcare, LLC dated August 10, 2021, in the aggregate principal amount of $ 2.4 18 0.2 1,026,758 1,488,453 Notes payable 1,026,758 2,917,390 Less current portion (1,026,758 ) (2,917,390 ) Notes payable - third parties, net of current portion $ - $ -
Schedule of Loan Payable Related Parties	At December 31, 2023 and 2022, loan payable - related party consisted of the following: Schedule of Loan Payable Related Parties December 31, December 31, Loan payable to Christopher Diamantis $ 2,168,000 $ 2,995,000 Less current portion of loan payable, related party (2,168,000 ) (2,995,000 ) Total loan payable, related party, net of current portion $ — $ —
Schedule of Debentures	The carrying amount of all outstanding debentures as of December 31, 2023 and 2022 was as follows: Schedule of Debentures December 31, December 31, March 2017 Debenture $ 2,580,240 $ 2,580,240 2018 Debentures 5,642,000 5,642,000 October 2022 Debentures - 400,000 Debentures, Gross 8,222,240 8,622,240 Less current portion - (8,622,240 ) Debentures, net of current portion $ 8,222,240 $ -

Operating Lease Obligations (Ta

Operating Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2023
Operating Lease Obligations
Schedule of Lease-related Assets and Liabilities	The following table presents our lease-related assets and liabilities at December 31, 2023 and 2022: Schedule of Lease-related Assets and Liabilities Balance Sheet Classification December 31, December 31, Assets: Total operating leases Right-of-use operating lease assets $ 359,194 $ 574,256 Liabilities: Current: Operating leases Right-of-use operating lease obligations $ 183,345 $ 215,063 Noncurrent: Operating leases Right-of-use operating lease obligations 175,849 359,193 Total lease liabilities $ 359,194 $ 574,256 Weighted-average remaining term: Operating leases 1.83 2.59 Weighted-average discount rate: Operating leases 13.0 % 13.0 %
Schedule of Lease Expense	The following table presents certain information related to lease expense for operating leases for the years ended December 31, 2023 and 2022: Schedule of Lease Expense Year Ended Year Ended December 31, 2022 Operating leases: Short-term lease expense (1) $ 342,114 $ 323,506 Total lease expense $ 342,114 $ 323,506 (1) Expense is included in general and administrative expenses in the consolidated statements of operations.
Schedule of Lease Supplemental Cash Flow Information	The following table presents supplemental cash flow information for the years ended December 31, 2023 and 2022: Schedule of Lease Supplemental Cash Flow Information Year Ended December 31, 2023 Year Ended December 31, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 265,307 $ 323,961
Schedule of Future Minimum Rentals Under Right-of-use Operating Leases	Aggregate future minimum lease payments under the right-of-use operating lease outstanding at December 31, 2023 are as follows: Schedule of Future Minimum Rentals Under Right-of-use Operating Leases Right-of-Use Twelve months ending December 31: 2024 $ 219,463 2025 186,496 2026 - 2027 - 2028 - Thereafter - Total 405,959 Less interest (46,765 ) Present value of minimum lease payments 359,194 Less current portion of operating lease obligation (183,345 ) Operating lease obligation, net of current portion $ 175,849

Fair Value, Derivative Financ_2

Fair Value, Derivative Financial Instruments and Deemed Dividends (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value Derivative Financial Instruments And Deemed Dividends
Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis	The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2023 and 2022: Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis Level 1 Level 2 Level 3 Total As of December 31, 2022: InnovaQor Series B-1 Preferred Stock $ - $ - $ 9,016,072 $ 9,016,072 Embedded conversion option of debenture - - 455,336 455,336 Total $ - $ - $ 9,471,408 $ 9,471,408 As of December 31, 2023: InnovaQor Series B-1 Preferred Stock $ - $ - $ 8,192,476 $ 8,192,476 Embedded conversion option of debenture - - 455,336 455,336 Total $ - $ - $ 8,647,812 $ 8,647,812

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Schedule of Stockholders’ Deficit	The following table summarizes the activity in the Company’s various classes of preferred stock included in Stockholders’ Deficit for the years ended December 31, 2023 and 2022: Schedule of Stockholders’ Deficit Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Series H Series L Series M Series N Series O Series P Total Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Balance December 31, 2022 10 $ - - 250,000 $ 2,500 20,810 $ 208 2,900 $ 29 8,685 $ 87 10,195 $ 102 292,600 $ 2,926 Conversion of Series F Preferred Stock into common stock - - - - - - - - - - - Conversion of Series F Preferred Stock into common stock, Shares - - - - - - - - - - - Issuances of Series P Preferred Stock - - - - - - - - - Issuances of Series P Preferred Stock, Shares - - - - - - - - - Conversions of Series N Preferred Stock into common stock - - - - - (496 ) (5 ) - - - - (496 ) (5 ) Conversions of Series O Preferred Stock into common stock - - - - - - - - (535 ) (5 ) - - (535 ) (5 ) Balance December 31, 2023 10 $ - - 250,000 $ 2,500 20,810 $ 208 2,404 $ 24 8,150 $ 82 10,195 $ 102 291,569 $ 2,916 Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Series H Series F Series L Series M Series N Series O Series P Total Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Balance December 31, 2021 10 $ - 1,750,000 $ 17,500 250,000 $ 2,500 20,810 $ 208 5,936 $ 59 9,900 $ 99 8,545 $ 85 2,045,201 $ 20,451 Balance 10 $ - 1,750,000 $ 17,500 250,000 $ 2,500 20,810 $ 208 5,936 $ 59 9,900 $ 99 8,545 $ 85 2,045,201 $ 20,451 Conversion of Series F Preferred Stock into common stock - - (1,750,000 ) (17,500 ) - - - - - - - - - (1,750,000 ) (17,500 ) Issuances of Series P Preferred Stock - - - - - - - - - - - - 1,650 17 1,650 17 Conversions of Series N Preferred Stock into common stock - - - - - - - (3,036 ) (30 ) - - - - (3,036 ) (30 ) Conversions of Series O Preferred Stock into common stock - - - - - - - - - - (1,215 ) (12 ) - - (1,215 ) (12 ) Balance December 31, 2022 10 $ - - $ - 250,000 $ 2,500 20,810 $ 208 2,900 $ 29 8,685 $ 87 10,195 $ 102 292,600 $ 2,926 Balance 10 $ - - $ - 250,000 $ 2,500 20,810 $ 208 2,900 $ 29 8,685 $ 87 10,195 $ 102 292,600 $ 2,926
Schedule of Stock Option Activity	Schedule of Stock Option Activity Number of options Weighted- average exercise price Weighted- average contractual term (years) Outstanding at December 31, 2021 26 $ 2,992,125 4.33 Granted - Expired - Outstanding at December 31, 2022 26 $ 2,992,125 3.37 Granted - Expired - Outstanding at December 31, 2023 26 $ 2,992,125 2.37 Exercisable at December 31, 2023 26 $ 2,992,125
Schedule of Stock Option Outstanding and Exercisable	The following table summarizes information with respect to stock options outstanding and exercisable by employees and directors at December 31, 2023: Schedule of Stock Option Outstanding and Exercisable Options outstanding Options vested and exercisable Exercise price Number outstanding Weighted average remaining contractual life (years) Weighted average exercise price Aggregate intrinsic value Number vested Weighted average exercise price Aggregate intrinsic value $ 10,000,000 5 2.25 $ 10,000,000 $ - 5 $ 10,000,000 $ - $ 5,000,000 5 2.25 $ 5,000,000 - 5 $ 5,000,000 - $ 269,580 8 2.33 $ 269,580 - 8 $ 269,580 - $ 80,906 8 2.54 $ 80,906 - 8 $ 80,906 - 26 2.37 $ 2,992,125 $ – 26 $ 2,992,125 $ -
Schedule of Warrants Activity	The following summarizes the information related to the number of shares of common stock issuable under outstanding warrants during the years ended December 31, 2023 and 2022: Schedule of Warrants Activity Number of Shares of Common Stock Issuable Warrants Weighted average exercise Balance at December 31, 2021 54,280,658 $ 1.43 Issuance of warrants - - Increase in number of shares of common stock issuable under 511,312,671,643 - Expiration of warrants (33,601,211 ) (0.9141 ) Balance at December 31, 2022 511,333,351,090 $ 0.00009 Issuance of warrants - - Expiration of warrants (1 ) (794,998 ) Balance at December 31, 2023 511,333,351,089 $ 0.00009

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Income Tax (Expense) Benefit	The provision for income taxes for the years ended December 31, 2023 and 2022 consists of the following: Schedule of Income Tax (Expense) Benefit Year Ended December 31, Year Ended December 31, Current Federal $ - $ (301,766 ) State (239,834 ) (11,083 ) Total Current (239,834 ) (312,849 ) Deferred Federal - - State - - Total Deferred - - Provision for income taxes $ (239,834 ) $ (312,849 )
Schedule of Effective Income Tax Rate Reconciliation	The following reconciles the Federal statutory income tax rate to the Company’s effective tax rate for the years ended December 31, 2023 and 2022: Schedule of Effective Income Tax Rate Reconciliation Year Ended December 31, Year Ended December 31, % % Federal statutory rate 21.0 % 21.0 % Permanent and other items 15.0 (17.0 ) Federal income taxes audit and other adjustments - - Change in valuation allowance (39.2 ) (14.5 ) Effective income tax rate (3.2) % (10.5 )%
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities are comprised of the following at December 31, 2023 and 2022: Schedule of Deferred Tax Assets and Liabilities December 31, December 31, Deferred income tax assets: Amortization $ 233,410 $ 375,821 Net operating loss carryforward 17,668,228 15,445,916 Allowance for doubtful accounts 393,001 387,818 Charitable contributions - 644 Stock options - 1,003,453 Accrued liabilities 5,121,508 1,826,839 HHS Provider Relief Funds 37,845 67,685 Employee retention credit - 292,282 HTS and AMSG basis difference - 878,709 Deferred state tax asset 4,043,616 4,089,682 Total deferred income tax assets 27,497,608 24,368,849 Deferred income tax liabilities: Right-of-use asset (93,875 ) - Depreciation (670,176 ) (583,812 ) Deferred tax asset, net 26,733,557 23,785,037 Less: valuation allowance (26,733,557 ) (23,785,037 ) Net deferred tax assets $ - $ -

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operation of Unaudited Balance Sheet and Operation Statement	Carrying amounts of major classes of liabilities of EPIC and the other non-operating subsidiaries included as part of discontinued operations in the consolidated balance sheets as of December 31, 2023 and 2022 consisted of the following: Schedule of Discontinued Operation of Unaudited Balance Sheet and Operation Statement December 31, December 31, 2022 Accounts payable $ 1,425,083 $ 1,425,083 Accrued expenses (1) 7,666,630 520,051 Finance lease obligation (2) 220,461 220,461 Current liabilities of discontinued operations $ 9,312,174 $ 2,165,595 (1) Included in accrued expenses at December 31, 2023 was $ 7.3 (2) As of December 31, 2023 and 2022, the Company was in default under the finance lease obligation. Therefore, the aggregate future minimum lease payments under this finance lease totaling $ 0.2 Line items constituting (loss) income from discontinued operations in the consolidated statements of operations for the years ended December 31, 2023 and 2022 consisted of the following: Consolidated (Loss) Income from Discontinued Operations: 2023 2022 Year Ended December 31, 2023 2022 Other (expense) income, net (1) $ (7,195,076 ) $ 56,844 Provision for income taxes - - (Loss) income from discontinued operations $ (7,195,076 ) $ 56,844 (1) Included in other expense for the year ended December 31, 2023 was $ 7.3

Supplemental Disclosure of Ca_2

Supplemental Disclosure of Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	Schedule of Supplemental Cash Flow Information 2023 2022 Year Ended December 31, 2023 2022 Cash paid for interest $ 419,177 $ 1,545,839 Cash paid for income taxes $ - $ - Non-cash investing and financing activities: Series F Preferred Stock converted into common stock $ - $ 17,500 Stated value of Series N Preferred Stock converted into common stock 496,530 3,035,570 Stated value of Series O Preferred Stock converted into common stock 535,500 1,214,910 Deemed dividends from issuances of Series P Preferred Stock - 333,333 Deemed dividends from down-round provisions of warrants - 330,543,036 Non-cash interest income 90,653 212,819 Original issue discounts on debt - 50,000

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Schedule of Warrants	Schedule of Warrants From March 21, 2024 to April 15, 2024 1,350,000,000 From April 16, 2024 to August 30, 2024 2,500,000,000 From August 31, 2024 to December 27, 2024 4,000,000,000 From December 28, 2024 to April 24, 2025 4,000,000,000 From April 25, 2025 to August 29, 2025 4,000,000,000
Schedule of Pro-forma Balance Sheet Data	Schedule of Pro-forma Balance Sheet Data Unaudited Pro Forma Balance Sheet Data December 31, 2023 Assets Related party notes receivable $ 5,603,543 Other current assets 875,216 Property and equipment, net 3,870,037 Investments in related parties 29,427,911 Other long-teem assets 739,647 Total assets $ 40,516,354 Liabilities and stockholders’ deficit Account payable and accrued expenses $ 19,155,690 Debt (includes related party loan of $2.2 million) 2,570,926 Other current liabilities 638,681 Current liabilities of discontinued operations 9,312,174 Long-term debt 8,222,240 Other long-term liabilities 6,368,549 Total liabilities 46,268,260 Stockholders’ deficit (5,751,906 ) Total liabilities and stockholders’ deficit $ 40,516,354
Schedule of Unaudited Pro forma Dispositions	Schedule of Unaudited Pro forma Dispositions 2023 2022 Unaudited Pro Forma Results of Operations Data Year Ended December 31, 2023 2022 Total revenue $ 1,274,718 $ 1,529,651 Net loss from continuing operations (4,639,798 ) (4,697,805 ) Deemed dividends - (330,876,369 ) Net loss from continuing operations available to common stockholders $ (4,639,798 ) $ (335,574,174 ) Net loss per common share: Basic and diluted net loss from continuing operation available to common stockholders $ (0.00 ) $ (0.03 )

Description of Business and B_2

Description of Business and Basis of Presentation (Details Narrative)				12 Months Ended
	Mar. 15, 2022 shares	Jun. 01, 2018 USD ($) ft²	Jan. 13, 2017 USD ($) ft² a	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Apr. 11, 2023	Mar. 14, 2022 shares	Jun. 01, 2018 a
Property, Plant and Equipment [Line Items]
Revenue				$ 18,700,000	$ 13,000,000
Accrued expenses				15,399,268	19,384,803
Working capital deficit				35,600,000
Stockholders' deficit				36,823,749	29,094,588
Net loss				$ 7,729,161	$ 3,293,055
Reverse stock split	1-for-10,000
Reverse stock splits, shares | shares	10,000
Common stock shares authorized | shares	250,000,000,000			250,000,000,000	250,000,000,000				50,000,000,000
Public Health and Social Services Emergency Fund [Member]
Property, Plant and Equipment [Line Items]
Relief funds				$ 100,000,000,000
HHS Provider Relief Funds [Member]
Property, Plant and Equipment [Line Items]
Relief funds				13,600,000
Revenue				13,300,000
Revenue recognized				300,000	$ 600,000	$ 4,400,000	$ 8,000,000
Accrued expenses				300,000
Revenue not recognized as liability				13,300,000
Settlement amount accrued				$ 1,200,000
Myrtle Recovery Centers, Inc [Member]
Property, Plant and Equipment [Line Items]
Ownership percentage								1.961%
Jamestown Regional Medical Center [Member]
Property, Plant and Equipment [Line Items]
Payments to acquire land		$ 700,000
Jamestown Regional Medical Center [Member] | Land [Member]
Property, Plant and Equipment [Line Items]
Area of land acquired		90,000								8
Asset Purchase Agreement [Member]
Property, Plant and Equipment [Line Items]
Purchase price			$ 1,000,000
Asset Purchase Agreement [Member] | Scott County Community Hospital [Member]
Property, Plant and Equipment [Line Items]
Area of land acquired | a			4.3
Asset Purchase Agreement [Member] | Scott County Community Hospital [Member] | Hospital Building [Member]
Property, Plant and Equipment [Line Items]
Area of land acquired | ft²			52,000
Asset Purchase Agreement [Member] | Scott County Community Hospital [Member] | Professional Building [Member]
Property, Plant and Equipment [Line Items]
Area of land acquired | ft²			6,300

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Liabilities	$ 57,096,480	$ 49,667,350
Estimated contractual allowance	40,400,000	32,000,000
Estimated implicit price concession	5,700,000	7,300,000
Allowance for adjustment of revenue	46,100,000	39,300,000
Net revenues	18,700,000	13,000,000
Change in fair value of investment	$ 823,596
Floor price per share	$ 0.052	$ 0.052
Warrant modification trigger, value	$ 0	$ 330,500,000
Preferred Stock [Member]
Deemed dividend		$ 300,000
InnovaQor Series B-1 Preferred Stock [Member]
Change in fair value of investment	800,000
Medicare [Member]
Liabilities	$ 2,300,000

Schedule of Basic and Diluted N

Schedule of Basic and Diluted Net Loss Per Share Available to Common Stockholders (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Net loss from continuing operations, net of noncontrolling interest	$ (534,085)	$ (3,349,899)
Deemed dividends		(330,876,369)
Net loss available to common stockholders, continuing operations	(534,085)	(334,226,268)
Net (loss) income from discontinued operations	(7,195,076)	56,844
Net loss available to common stockholders	$ (7,729,161)	$ (334,169,424)
Net loss per share of common stock available to common stockholders - basic:
Continuing operations - basic	$ 0	$ (0.03)
Continuing operations - diluted	0	(0.03)
Discontinued operations - basic	0	0
Discontinued operations - diluted	0	0
Total basic	0	(0.03)
Total diluted	$ 0	$ (0.03)
Basic	32,825,519,517	9,992,238,468
Diluted	32,825,519,517	9,992,238,468

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	981,361,817,781	993,106,595,560
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	511,333,351,089	511,333,351,090
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	441,250,633,333	452,995,411,111
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	28,777,833,333	28,777,833,333
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares	26	26

Loss per Share (Details Narrati

Loss per Share (Details Narrative) - shares			12 Months Ended
	Feb. 04, 2025	Jan. 01, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities potential				981,361,817,781	993,106,595,560
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock warrants outstanding				101.3
Number of warrants expired				1	33,601,211
Warrant [Member] | Forecast [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of warrants expired			101,300,000,000
Subsequent Event [Member] | Common Stock And Common Stock Equivalents [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities potential	424,200,000,000
Subsequent Event [Member] | Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of warrants exercised		2,500,000,000

Schedule of Accounts Receivable

Schedule of Accounts Receivable (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Accounts receivable, gross	$ 12,799,901	$ 13,046,646
Allowance for contractual obligations	(8,208,745)	(8,529,904)
Allowance for doubtful accounts	(1,503,736)	(1,405,773)
Accounts receivable, net	$ 3,087,420	$ 3,110,969

Accounts Receivable and Incom_3

Accounts Receivable and Income Tax Refund Receivable (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Income Taxes Receivable, Current	$ 837,460	$ 837,460

Schedule of Property and Equipm

Schedule of Property and Equipment, Net (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 7,070,028	$ 7,035,318
Less accumulated depreciation	(2,748,729)	(2,841,019)
Property and equipment, net	4,321,299	4,194,299
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,268,028	4,181,434
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	550,700	550,700
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,746,412	1,637,585
Equipment Under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	189,711	189,711
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	123,497	38,798
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	151,790	2,160
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	32,115	32,115
Software Development [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 7,775	$ 402,815

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 0.3	$ 0.5
Building [Member]
Property, Plant and Equipment [Line Items]
Depreciation term	39 years
Building [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Depreciation term	3 years
Building [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Depreciation term	7 years

Intangible Asset (Details Narra

Intangible Asset (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset	$ 259,443	$ 259,443

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued payroll and related liabilities	$ 8,338,517	$ 8,433,076
HHS Provider Relief Funds	144,805	552,099
Accrued interest	6,663,561	5,732,306
Accrued legal expenses and settlements	1,797,170	534,550
Medicare cost report settlement reserves	2,264,847	2,101,837
Other accrued expenses	2,383,068	2,030,935
Total accrued expenses	21,591,968	19,384,803
Less current portion of accrued expenses	(15,399,268)	(19,384,803)
Accrued expenses long-term	$ 6,192,700

Accrued Expenses (Details Narra

Accrued Expenses (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Employee related liabilities current and non current	$ 7,300,000	$ 7,000,000
Accrued expenses	21,591,968	19,384,803
Accrued expenses long-term	6,192,700
HHS Provider Relief Funds [Member]
Line of Credit Facility [Line Items]
Accrued expenses	$ 100,000	$ 600,000

Schedule of Debt (Details)

Schedule of Debt (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Notes payable- third parties	$ 1,026,758	$ 2,917,390
Loan payable – related party	2,168,000	2,995,000
Debentures	8,222,240	8,622,240
Total debt	11,416,998	14,534,630
Less current portion of debt	(3,194,758)	(14,534,630)
Total debt, net of current portion	$ 8,222,240

Schedule of Notes Payable Third

Schedule of Notes Payable Third Parties (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Notes payable	$ 1,026,758	$ 2,917,390
Less current portion	(1,026,758)	(2,917,390)
Notes payable - third parties, net of current portion
Notes Payable Third Parties One [Member]
Short-Term Debt [Line Items]
Notes payable		291,557
Notes Payable Third Parties Two [Member]
Short-Term Debt [Line Items]
Notes payable		1,137,380
Notes Payable Third Parties Three [Member]
Short-Term Debt [Line Items]
Notes payable	$ 1,026,758	$ 1,488,453

Schedule of Notes Payable Thi_2

Schedule of Notes Payable Third Parties (Details) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2023	Aug. 09, 2023
Short-Term Debt [Line Items]
Original principal amount		$ 100,000
Notes Payable Third Parties One [Member]
Short-Term Debt [Line Items]
Original principal amount	$ 500,000
Notes Payable Third Parties Two [Member]
Short-Term Debt [Line Items]
Original principal amount	1,900,000
Debt discount	300,000
Debt fee amount	100,000
Notes Payable Third Parties Three [Member]
Short-Term Debt [Line Items]
Original principal amount	$ 2,400,000
Debt instruments interest rate	18%
Debt instrument periodic payment	$ 200,000

Schedule of Loan Payable Relate

Schedule of Loan Payable Related Parties (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Loan payable to Christopher Diamantis	$ 2,168,000	$ 2,995,000
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Loan payable to Christopher Diamantis	2,168,000	2,995,000
Less current portion of loan payable, related party	(2,168,000)	(2,995,000)
Total loan payable, related party, net of current portion

Schedule of Debentures (Details

Schedule of Debentures (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Debentures, Gross	$ 11,416,998	$ 14,534,630
Less current portion	(3,194,758)	(14,534,630)
Debentures, net of current portion	8,222,240
March 2017 Debentures [Member]
Short-Term Debt [Line Items]
Debentures, Gross	2,600,000	2,600,000
Institutional Investors [Member]
Short-Term Debt [Line Items]
Debentures, Gross	8,222,240	8,622,240
Less current portion		(8,622,240)
Debentures, net of current portion	8,222,240
Institutional Investors [Member] | March 2017 Debentures [Member]
Short-Term Debt [Line Items]
Debentures, Gross	2,580,240	2,580,240
Institutional Investors [Member] | 2018 Debentures [Member]
Short-Term Debt [Line Items]
Debentures, Gross	5,642,000	5,642,000
Institutional Investors [Member] | October 2022 [Member]
Short-Term Debt [Line Items]
Debentures, Gross		$ 400,000

Debt (Details Narrative)

Debt (Details Narrative) - USD ($) $ / shares in Units, shares in Millions										12 Months Ended
	Oct. 25, 2023	Jun. 01, 2023	Apr. 12, 2023	Mar. 12, 2023	Feb. 12, 2023	Jan. 12, 2023	Dec. 15, 2022	Oct. 12, 2022	Aug. 10, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2020	Aug. 09, 2023	May 12, 2023	Jan. 18, 2022	May 31, 2020	Sep. 27, 2019	Dec. 31, 2018	Apr. 23, 2018
Short-Term Debt [Line Items]
Notes payable
Initial notes payable										1,026,758	2,917,390
Payments of debentures										400,000	150,000
Debt face amount													$ 100,000
Repayments of related party debt										1,407,000	182,000
Notes payable										1,026,758	2,917,390
Proceeds from issuance of debt											500,000
Gain on forgiveness of debt										200,000	334,819
Current portion of loan payable, related party										2,168,000	2,995,000
Outstanding debentures										11,416,998	14,534,630
Conversion of convertible securities
Amortization of original issue discount											50,000
Deemed dividends										0	330,500,000
Western Healthcare LLC [Member]
Short-Term Debt [Line Items]
Reduction of aggregate principal amount of notes														$ 400,000
Aggregate principal amount of notes exchange for cash payments														$ 200,000
Gain on forgiveness of debt										200,000
Related Party [Member]
Short-Term Debt [Line Items]
Current portion of loan payable, related party										2,168,000	2,995,000
Anthony O Killough [Member]
Short-Term Debt [Line Items]
Payments of debentures											1,100,000
Debt face amount																	$ 1,900,000
Repayments of related party debt											350,000
Anthony O Killough [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Notes payable											300,000
Mr Diamantis and Mr O' Killough [Member]
Short-Term Debt [Line Items]
Non-payment of promissory note																$ 2,200,000
Mr. Christopher Diamantis [Member]
Short-Term Debt [Line Items]
Payments of debentures										2,200,000
Gain on legal settlement										600,000
Repayments of related party debt										1,400,000	1,000,000	$ 450,000
Proceeds from issuance of debt										$ 580,000
Interest rate										10%
Current portion of loan payable, related party										$ 600,000	1,100,000
Accrued interest										100,000	100,000
Payment of accrued interest										100,000	400,000
Interest remained										0	0
Mr. Christopher Diamantis [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Notes payable															$ 750,000
Settlement Agreement [Member]
Short-Term Debt [Line Items]
Gain on legal settlement										36,443
Settlement Agreement [Member] | Western Health Care [Member]
Short-Term Debt [Line Items]
Payments of debentures									$ 200,000
Debt face amount									$ 2,400,000
Interest rate									18%
Amendment and Waiver Agreement [Member]
Short-Term Debt [Line Items]
Accrued interest	$ 6,200,000									6,200,000
Debentures										$ 8,200,000
Tegal Notes [Member]
Short-Term Debt [Line Items]
Notes payable		$ 462,500																	$ 384,384
Initial notes payable		200,000
Payments of debentures		$ 43,750
March 2017 Debentures [Member]
Short-Term Debt [Line Items]
Interest rate										18%
Outstanding debentures										$ 2,600,000	2,600,000
Late payment penalty percentage										30%
Late payment fee amount										$ 600,000
Interest expense on debentures										$ 300,000	$ 500,000
Debt conversion per share										$ 0.00009
Debt conversion converted instrument shares issued										28,700
2018 Debentures [Member]
Short-Term Debt [Line Items]
Debt face amount																		$ 14,500,000
Interest rate										18%
Late payment penalty percentage										30%	30%
Late payment fee amount										$ 1,300,000	$ 1,300,000
Interest expense on debentures										$ 800,000	1,000,000
Debt conversion per share										$ 0.052
Debt conversion converted instrument shares issued										108.5
Debt conversion converted instrument amount										$ 5,600,000	5,600,000
October 2022 [Member]
Short-Term Debt [Line Items]
Proceeds from issuance of debt								$ 500,000
Interest expense on debentures										1,100,000	1,500,000
Conversion of convertible securities								550,000
Amortization of original issue discount								$ 50,000			50,000
Non cash interest expense											50,000
Payments for rent							$ 150,000
Accrued interest										$ 6,200,000	$ 5,100,000
October 2022 [Member] | Monthly Payment Four [Member]
Short-Term Debt [Line Items]
Payments for rent			$ 100,000	$ 100,000	$ 100,000	$ 100,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)			12 Months Ended
	Aug. 09, 2023	Jul. 02, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2020
Related Party Transaction [Line Items]
Note receivable from related party				$ 3,087,420	$ 3,110,969
Repayment of related party				1,407,000	182,000
Principal amount	$ 100,000
Promissory Note [Member]
Related Party Transaction [Line Items]
Other Liabilities				1,530,116
New Promissory Note [Member]
Related Party Transaction [Line Items]
Other Liabilities				1,198,191
Alcimede Limited [Member]
Related Party Transaction [Line Items]
Proffestional fees				500,000	400,000
InnovaQor [Member]
Related Party Transaction [Line Items]
Proffestional fees				400,000	200,000
Note receivable from related party				2,700,000	1,500,000
Working capital advance				$ 1,200,000	$ 1,500,000
Outstanding receivable from related party		$ 803,416
Repayment of related party		$ 883,757
Original issue discount		10%
Principal amount, percentage	5%			18%	18%
Original issue discount as interest income			$ 271,694		$ 200,000
Debt instrument, maturity date extension	June 30, 2023 to December 31, 2023
Payment for rent				$ 10,400
InnovaQor [Member] | Forecast [Member]
Related Party Transaction [Line Items]
Working capital advance			$ 300,000
InnovaQor [Member] | Promissory Note [Member]
Related Party Transaction [Line Items]
Original issue discount				10%	10%
Principal amount				$ 3,000,000	$ 1,457,253
Debt Instrument, Unamortized Discount				$ 271,693	$ 132,478
Debt Instrument, Maturity Date				Dec. 31, 2024	Jun. 30, 2023
InnovaQor [Member] | New Capital Secured [Member]
Related Party Transaction [Line Items]
Original issue discount				25%	25%
Related Party [Member] | Promissory Note [Member]
Related Party Transaction [Line Items]
Other Liabilities					$ 883,757
Related Party [Member] | New Promissory Note [Member]
Related Party Transaction [Line Items]
Other Liabilities					$ 441,018
MsKristi Dymond [Member]
Related Party Transaction [Line Items]
Loans receivable						$ 82,500

Schedule of Lease-related Asset

Schedule of Lease-related Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating Lease Obligations
Right-of-use operating lease assets	$ 359,194	$ 574,256
Right-of-use operating lease assets, current	183,345	215,063
Right-of-use operating lease assets, noncurrent	175,849	359,193
Total lease liabilities	$ 359,194	$ 574,256
Weighted-average remaining term: Operating leases	1 year 9 months 29 days	2 years 7 months 2 days
Weighted-average discount rate: Operating leases	13%	13%

Schedule of Lease Expense (Deta

Schedule of Lease Expense (Details) - USD ($)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Operating Lease Obligations
Short-term lease expense	[1]	$ 342,114	$ 323,506
Total lease expense		$ 342,114	$ 323,506
[1]Expense is included in general and administrative expenses in the consolidated statements of operations.

Schedule of Lease Supplemental

Schedule of Lease Supplemental Cash Flow Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Lease Obligations
Operating cash flows for operating leases	$ 265,307	$ 323,961

Schedule of Future Minimum Rent

Schedule of Future Minimum Rentals Under Right-of-use Operating Leases (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Twelve months ending December 31:
2024	$ 219,463
2025	186,496
2026
2027
2028
Thereafter
Total	405,959
Less interest	(46,765)
Present value of minimum lease payments	359,194
Less current portion of operating lease obligation	(183,345)	$ (215,063)
Operating lease obligation, net of current portion	$ 175,849	$ 359,193

Schedule of Fair Value of Asset

Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of assets and liabilities	$ 8,647,812	$ 9,471,408
Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of assets and liabilities
Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of assets and liabilities
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of assets and liabilities	8,647,812	9,471,408
InnovaQor SeriesB Preferred Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of assets and liabilities	8,192,476	9,016,072
InnovaQor SeriesB Preferred Stock [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of assets and liabilities
InnovaQor SeriesB Preferred Stock [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of assets and liabilities
InnovaQor SeriesB Preferred Stock [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of assets and liabilities	8,192,476	9,016,072
Embedded Conversion Options [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of assets and liabilities	455,336	455,336
Embedded Conversion Options [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of assets and liabilities
Embedded Conversion Options [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of assets and liabilities
Embedded Conversion Options [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of assets and liabilities	$ 455,336	$ 455,336

Fair Value, Derivative Financ_3

Fair Value, Derivative Financial Instruments and Deemed Dividends (Details Narrative)		12 Months Ended
	Apr. 02, 2022 shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 shares
Fair value of stock		$ 8,647,812	$ 9,471,408
Change in fair value		$ (823,596)
Market price, percentage		85%
Change in value of embedded conversion option		$ 0	0
Provisions for deemed dividends		0	$ 330,500,000
Preferred Stock [Member]
Stock issued during period, shares, new issues | shares			1,650
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Volatility ranging, minimum			0
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Volatility ranging, minimum			0.0273
Measurement Input, Expected Term [Member] | Minimum [Member]
Expected term			3 days
Measurement Input, Expected Term [Member] | Maximum [Member]
Expected term			2 years 5 months 12 days
Measurement Input, Option Volatility [Member] | Minimum [Member]
Volatility ranging, minimum			0.0194
Measurement Input, Option Volatility [Member] | Maximum [Member]
Volatility ranging, minimum			15.640
InnovaQor Series B-1 Preferred Stock [Member]
Fair value of stock		8,192,476	$ 9,016,072
Change in fair value		823,596
Embedded Conversion Options [Member]
Fair value of stock		455,336	455,336
Convertible debenture outstanding		$ 455,336	$ 455,336
InnovaQor Series B-1 Preferred Stock [Member]
Stock issued during period, shares, new issues | shares		14,850	14,850	14,950
Number of preferred stock used to settle an outstanding liability | shares				100
Change in fair value		$ (800,000)
InnovaQor Series B-1 Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Stock measurement input		3.84	0.84
InnovaQor Series B-1 Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Stock measurement input		215	250
InnovaQor Series B-1 Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Exit period		5 years	5 years
InnovaQor Series B-1 Preferred Stock [Member] | Measurement Input, Discount Rate [Member]
Stock measurement input		45	35
Series P Preferred Stock [Member]
Stock issued during period, shares, new issues | shares	550
Deemed dividends			$ 300,000
Series P Preferred Stock [Member] | Preferred Stock [Member]
Deemed dividends			$ 300,000

Schedule of Stockholders_ Defic

Schedule of Stockholders’ Deficit (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ (29,094,588)
Balance	(36,823,749)	$ (29,094,588)
Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 2,926	$ 20,451
Balance, shares	292,600	2,045,201
Conversion of Series F Preferred Stock into common stock		$ (17,500)
Conversion of Series F Preferred Stock for common stock, shares		(1,750,000)
Issuances of Series P Preferred Stock		$ 17
Issuance of Series P Preferred Stock, Shares		1,650
Conversions of Series N Preferred Stock into common stock	$ (5)	$ (30)
Conversions of Series N Preferred Stock into common stock, Shares	(496)	(3,036)
Conversions of Series O Preferred Stock into common stock	$ (5)	$ (12)
Conversions of Series O Preferred Stock into common stock, Shares	(535)	(1,215)
Balance	$ 2,916	$ 2,926
Balance, shares	291,569	292,600
Preferred Stock [Member] | Preferred Stock Series H [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance
Balance, shares	10	10
Conversion of Series F Preferred Stock into common stock
Conversion of Series F Preferred Stock for common stock, shares
Issuances of Series P Preferred Stock
Issuance of Series P Preferred Stock, Shares
Conversions of Series N Preferred Stock into common stock
Conversions of Series O Preferred Stock into common stock
Balance
Balance, shares	10	10
Preferred Stock [Member] | Preferred Stock Series F [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance		$ 17,500
Balance, shares		1,750,000
Conversion of Series F Preferred Stock into common stock		$ (17,500)
Conversion of Series F Preferred Stock for common stock, shares		(1,750,000)
Issuances of Series P Preferred Stock
Conversions of Series N Preferred Stock into common stock
Conversions of Series O Preferred Stock into common stock
Balance
Balance, shares
Preferred Stock [Member] | Preferred Stock Series L [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 2,500	$ 2,500
Balance, shares	250,000	250,000
Conversion of Series F Preferred Stock into common stock
Conversion of Series F Preferred Stock for common stock, shares
Issuances of Series P Preferred Stock
Issuance of Series P Preferred Stock, Shares
Conversions of Series N Preferred Stock into common stock
Conversions of Series O Preferred Stock into common stock
Balance	$ 2,500	$ 2,500
Balance, shares	250,000	250,000
Preferred Stock [Member] | Preferred Stock Series M [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 208	$ 208
Balance, shares	20,810	20,810
Conversion of Series F Preferred Stock into common stock
Issuances of Series P Preferred Stock
Conversions of Series O Preferred Stock into common stock
Balance	$ 208	$ 208
Balance, shares	20,810	20,810
Preferred Stock [Member] | Preferred Stock Series N [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 29	$ 59
Balance, shares	2,900	5,936
Conversion of Series F Preferred Stock into common stock
Issuances of Series P Preferred Stock
Conversions of Series N Preferred Stock into common stock	$ (5)	$ (30)
Conversions of Series N Preferred Stock into common stock, Shares	(496)	(3,036)
Conversions of Series O Preferred Stock into common stock
Conversions of Series O Preferred Stock into common stock, Shares	(535)
Balance	$ 24	$ 29
Balance, shares	2,404	2,900
Preferred Stock [Member] | Preferred Stock Series O [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 87	$ 99
Balance, shares	8,685	9,900
Conversion of Series F Preferred Stock into common stock
Conversion of Series F Preferred Stock for common stock, shares
Issuances of Series P Preferred Stock
Issuance of Series P Preferred Stock, Shares
Conversions of Series N Preferred Stock into common stock
Conversions of Series O Preferred Stock into common stock	(5)	$ (12)
Conversions of Series O Preferred Stock into common stock, Shares		(1,215)
Balance	$ 82	$ 87
Balance, shares	8,150	8,685
Preferred Stock [Member] | Preferred Stock Series P [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 102	$ 85
Balance, shares	10,195	8,545
Conversion of Series F Preferred Stock into common stock
Conversion of Series F Preferred Stock for common stock, shares
Issuances of Series P Preferred Stock		$ 17
Issuance of Series P Preferred Stock, Shares		1,650
Conversions of Series N Preferred Stock into common stock
Conversions of Series O Preferred Stock into common stock
Balance	$ 102	$ 102
Balance, shares	10,195	10,195

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Number of Options Outstanding, Ending balance	26	26
Weighted-average exercise price, Outstanding, Ending balance	$ 2,992,125	$ 2,992,125
Weighted-average contractual term, Ending	2 years 4 months 13 days	3 years 4 months 13 days	4 years 3 months 29 days
Number of Options Outstanding, Granted
Number of Options Outstanding, Expired
Number of Options Outstanding, Ending balance	26	26	26
Weighted-average exercise price, Outstanding, Ending balance	$ 2,992,125	$ 2,992,125	$ 2,992,125
Number of Options Exercisable, Ending balance	26
Weighted-average exercise price, Exercisable, Ending balance	$ 2,992,125

Schedule of Stock Option Outsta

Schedule of Stock Option Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, Number outstanding | shares	26
Options outstanding, Weighted average remaining contractual life (years)	2 years 4 months 13 days
Options outstanding, Weighted average exercise	$ 2,992,125
Options outstanding, Aggregate intrinsic value | $
Options vested and exercisable, Number vested | shares	26
Options vested and exercisable Weighted average exercise price	$ 2,992,125
Options vested and exercisable Aggregate intrinsic value | $
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, Exercise price	$ 10,000,000
Options outstanding, Number outstanding | shares	5
Options outstanding, Weighted average remaining contractual life (years)	2 years 3 months
Options outstanding, Weighted average exercise	$ 10,000,000
Options outstanding, Aggregate intrinsic value | $
Options vested and exercisable, Number vested | shares	5
Options vested and exercisable Weighted average exercise price	$ 10,000,000
Options vested and exercisable Aggregate intrinsic value | $
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, Exercise price	$ 5,000,000
Options outstanding, Number outstanding | shares	5
Options outstanding, Weighted average remaining contractual life (years)	2 years 3 months
Options outstanding, Weighted average exercise	$ 5,000,000
Options outstanding, Aggregate intrinsic value | $
Options vested and exercisable, Number vested | shares	5
Options vested and exercisable Weighted average exercise price	$ 5,000,000
Options vested and exercisable Aggregate intrinsic value | $
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, Exercise price	$ 269,580
Options outstanding, Number outstanding | shares	8
Options outstanding, Weighted average remaining contractual life (years)	2 years 3 months 29 days
Options outstanding, Weighted average exercise	$ 269,580
Options outstanding, Aggregate intrinsic value | $
Options vested and exercisable, Number vested | shares	8
Options vested and exercisable Weighted average exercise price	$ 269,580
Options vested and exercisable Aggregate intrinsic value | $
Exercise Price Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, Exercise price	$ 80,906
Options outstanding, Number outstanding | shares	8
Options outstanding, Weighted average remaining contractual life (years)	2 years 6 months 14 days
Options outstanding, Weighted average exercise	$ 80,906
Options outstanding, Aggregate intrinsic value | $
Options vested and exercisable, Number vested | shares	8
Options vested and exercisable Weighted average exercise price	$ 80,906
Options vested and exercisable Aggregate intrinsic value | $

Schedule of Warrants Activity (

Schedule of Warrants Activity (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares of Common Stock Issuable for Warrants, Beginning Balance	511,333,351,090	54,280,658
Weighted average exercise price, Beginning Balance	$ 0.00009	$ 1.43
Number of Shares of Common Stock Issuable for Warrants, issuance of warrants
Weighted average exercise price issuance of warrants
Increase in number of shares of common stock issuable under warrants during the period as a result of down round provisions		511,312,671,643
Number of Shares of Common Stock Issuable for Warrants,expiration of warrants	(1)	(33,601,211)
Weighted average exercise price expiration of warrants	$ (794,998)	$ (0.9141)
Number of Shares of Common Stock Issuable for Warrants, Ending Balance	511,333,351,089	511,333,351,090
Weighted average exercise price, Ending Balance	$ 0.00009	$ 0.00009

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative) - USD ($)										12 Months Ended
	Feb. 03, 2025	Dec. 31, 2023	Apr. 02, 2022	Mar. 22, 2022	Mar. 11, 2022	Nov. 07, 2021	Aug. 27, 2021	Jun. 30, 2020	Sep. 27, 2017	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 27, 2022	Mar. 15, 2022	Mar. 14, 2022	Oct. 28, 2021	Sep. 07, 2021	Aug. 10, 2021	Jul. 12, 2021	May 18, 2021	May 10, 2021	Aug. 31, 2020
Class of Stock [Line Items]
Common stock, shares authorized		250,000,000,000									250,000,000,000	250,000,000,000			250,000,000,000	50,000,000,000
Common stock, par value		$ 0.0001									$ 0.0001	$ 0.0001
Preferred stock shares authorized		5,000,000									5,000,000
Preferred stock par value		$ 0.01									$ 0.01
Number of common stock issued, value												$ 1,500,000
Conversion price discount percentage											90%
Gain loss on extinguishment of debt											$ 200,000	334,819
Long-term debt		$ 11,416,998									$ 11,416,998	$ 14,534,630
Common stock shares issued		40,551,322,257									40,551,322,257	29,084,322,257
Common stock shares outstanding		40,551,322,257									40,551,322,257	29,084,322,257
Weighted average period											2 years 4 months 13 days	3 years 4 months 13 days	4 years 3 months 29 days
Warrant maturity date						Mar. 21, 2024
March 2017 Debentures [Member]
Class of Stock [Line Items]
Exercise price per share		$ 0.00009									$ 0.00009
Number of warrants exercisable											190,000,000,000
Two Thousand and Seven Equity Plan [Member]
Class of Stock [Line Items]
Weighted average period											2 years 4 months 13 days
Intrinsic value of options exercisable		$ 0									$ 0	$ 0
Common Stock [Member]
Class of Stock [Line Items]
Number of common stock issued, value
Conversion of convertible securities, common shares											5,517,000,000	15,994,077,566
Stock issued during period, shares, new issues
Number of preferred shares converted											535	13,100,000,000
Conversion of Stock, Shares Issued		26,700,000,000
Warrant [Member]
Class of Stock [Line Items]
Common stock exercisable											511,300,000,000
Number of warrants issued as anti dilution provision												511,312,671,643
Warrant [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Warrants exercised										2,500,000,000
Warrants expired										508,800,000,000
March Warrants [Member]
Class of Stock [Line Items]
Number of warrants issued as anti dilution provision											507,600,000,000
Series B Warrant [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Warrants expired										101,300,000,000
Series B Warrant [Member] | March 2017 Debentures [Member]
Class of Stock [Line Items]
Number of warrants exercisable				127,600,000,000							2,500,000,000
Series C Warrant [Member] | March 2017 Debentures [Member]
Class of Stock [Line Items]
Number of warrants exercisable											190,000,000,000
Warrant term		5 years									5 years
Series B Warrants [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Warrants expired										101,300,000,000
Mr. Diamantis [Member] | Common Stock [Member]
Class of Stock [Line Items]
Conversion of convertible securities, common shares													45
Holders [Member] | Common Stock [Member]
Class of Stock [Line Items]
Stock issued during period, shares, conversion of units												13,100,000,000
Institutional Investors [Member]
Class of Stock [Line Items]
Long-term debt		$ 8,222,240									$ 8,222,240	$ 8,622,240
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares outstanding		10									10
Series L Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares outstanding		250,000									250,000
Series M Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		30,000									30,000	30,000
Preferred stock par value		$ 0.01									$ 0.01	$ 0.01
Preferred stock shares outstanding		20,810.35									20,810.35	20,810
Preferred stock shares issued		20,810									20,810	20,810
Preferred stock par value		$ 1,000									$ 1,000	$ 1,000
Conversion price discount percentage											90%
Dividend rate											10%
Preferred stock voting percentage											51%
Conversion of Stock, Shares Issued											208,100,000,000
Series M Preferred Stock [Member] | Mr. Diamantis [Member]
Class of Stock [Line Items]
Preferred stock par value								$ 0.01
Preferred stock par value								$ 1,000
Gain loss on extinguishment of debt								$ 18,800,000
Stock repurchased during period, shares								22,000
Conversion of convertible securities, common shares													610.65
Conversion of convertible securities, par value													$ 600,000
Number of preferred shares converted											20,810.35
Series M Preferred Stock [Member] | Mr. Diamantis [Member] | Exchange Agreement [Member]
Class of Stock [Line Items]
Number of stock exchange							570
Stock exchanged value							$ 600,000
Stock issued during period, shares, new issues							9,500
Number of warrants exercisable into common stock		3,700,000,000					4,750				3,700,000,000
Exercise price per share		$ 0.00009					$ 70				$ 0.00009
Series N Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		50,000									50,000	50,000
Preferred stock par value		$ 0.01									$ 0.01	$ 0.01
Preferred stock shares outstanding		2,403.78									2,403.78	2,900
Preferred stock shares issued		2,404									2,404	2,900
Preferred stock par value		$ 1,000									$ 1,000	$ 1,000
Conversion price discount percentage											90%
Dividend rate											10%
Stock issued during period, shares, new issues											5,500,000,000	16,000,000,000
Number of preferred shares converted		2,403.78										3,036
Number of common shares converted											5,500,000,000
Series N Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of preferred shares converted											496
Series N Preferred Stock [Member] | Board of Directors [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		5,000,000									5,000,000
Preferred stock par value		$ 1,000									$ 1,000
Series N Preferred Stock [Member] | Holders [Member]
Class of Stock [Line Items]
Stock issued during period, shares, conversion of units											496.53	3,035.57
Stock issued during period, value, conversion of units											$ 500,000	$ 3,000,000
Series O Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		10,000									10,000	10,000
Preferred stock par value		$ 0.01									$ 0.01	$ 0.01
Preferred stock shares outstanding		8,149.59									8,149.59	8,685
Preferred stock shares issued		8,150									8,150	8,685	9,900					550	1,100	1,100	1,100	1,100
Preferred stock par value		$ 1,000									$ 1,000	$ 1,000	$ 1,000
Dividend rate											10%
Number of preferred shares converted											8,149.59	1,215
Stock issued during period, shares, conversion of units											535.5	1,214.9
Preferred stock and received proceeds													$ 9,000,000
Series O Preferred Stock [Member] | Forecast [Member]
Class of Stock [Line Items]
Number of preferred shares converted	8,000
Series O Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Preferred stock shares issued																	4,400
Series O Preferred Stock [Member] | Securities Purchase Agreement [Member] | Maximum [Member]
Class of Stock [Line Items]
Preferred stock shares issued												4,400
Series O Preferred Stock [Member] | Second Securities Purchase Agreement [Member] | Maximum [Member]
Class of Stock [Line Items]
Preferred stock shares issued																		1,100
Series O Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of preferred shares converted											6,000,000,000
Conversion of Stock, Shares Issued											90,600,000,000
Series O Preferred Stock [Member] | Holders [Member]
Class of Stock [Line Items]
Stock issued during period, value, conversion of units											$ 500,000	$ 1,200,000
Series P Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		30,000									30,000	30,000
Preferred stock par value		$ 0.01									$ 0.01	$ 0.01
Preferred stock shares outstanding		10,194.87									10,194.87	10,195
Preferred stock shares issued		10,195									10,195	10,195
Preferred stock par value		$ 1,000									$ 1,000	$ 1,000
Conversion price discount percentage											90%
Dividend rate											10%
Stock issued during period, shares, new issues			550
Number of preferred shares converted											10,194.87
Conversion of Stock, Shares Issued											113,300,000,000
Preferred stock and received proceeds			$ 500,000
Deemed dividends												$ 300,000
Preferred stock, conversion price		$ 0.00009									$ 0.00009
Series P Preferred Stock [Member] | Exchange Aggrement [Member]
Class of Stock [Line Items]
Preferred stock par value						$ 1,000
Warrants and rights outstanding						$ 1,100,000
Non-convertible debentures						4,500,000
Long-term debt						$ 1,500,000
Indebtedness and accrued interest, shares						8,544.87
Series P Preferred Stock [Member] | Institutional Investors [Member]
Class of Stock [Line Items]
Stock issued during period, shares, new issues					1,100
Preferred stock and received proceeds					$ 1,000,000
Conversion price discount percentage					10%
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares outstanding														17,500
Number of common stock issued, value									$ 174,097
Number of preferred shares converted												1,750,000
Number of common shares converted												16,000,000,000
Series H Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		14,202									14,202	14,202
Preferred stock par value		$ 0.01									$ 0.01	$ 0.01
Preferred stock shares outstanding		10									10	10
Preferred stock shares issued		10									10	10
Preferred stock par value		$ 1,000									$ 1,000	$ 1,000
Conversion price discount percentage											85%
Series L Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		250,000									250,000	250,000
Preferred stock par value		$ 0.01									$ 0.01	$ 0.01
Preferred stock shares outstanding		250,000									250,000	250,000
Preferred stock shares issued		250,000									250,000	250,000
Preferred stock par value		$ 1									$ 1	$ 1
Conversion price per share		0.0001									0.0001
Series L Preferred Stock [Member] | Alcimede LLC [Member]
Class of Stock [Line Items]
Preferred stock par value		$ 1									$ 1
Series I-1 and Series I-2 Preferred Stock [Member] | Exchange and Redemption Agreement [Member]
Class of Stock [Line Items]
Preferred stock shares outstanding																							30,435.52
Series O Preferred Stock Two [Member] | Closing One [Member]
Class of Stock [Line Items]
Preferred stock shares issued																	2,200
Series O Preferred Stock Two [Member] | Closing Two [Member]
Class of Stock [Line Items]
Preferred stock shares issued																	2,200
Common Stock [Member] | Holders [Member]
Class of Stock [Line Items]
Stock issued during period, shares, conversion of units											6,000,000,000

Schedule of Income Tax (Expense

Schedule of Income Tax (Expense) Benefit (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal		$ (301,766)
State	(239,834)	(11,083)
Total Current	(239,834)	(312,849)
Federal
State
Total Deferred
Provision for income taxes	$ (239,834)	$ (312,849)

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal statutory rate	21%	21%
Permanent and other items	15%	(17.00%)
Federal income taxes audit and other adjustments
Change in valuation allowance	(39.20%)	(14.50%)
Effective income tax rate	(3.20%)	(10.50%)

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Amortization	$ 233,410	$ 375,821
Net operating loss carryforward	17,668,228	15,445,916
Allowance for doubtful accounts	393,001	387,818
Charitable contributions		644
Stock options		1,003,453
Accrued liabilities	5,121,508	1,826,839
HHS Provider Relief Funds	37,845	67,685
Employee retention credit		292,282
HTS and AMSG basis difference		878,709
Deferred state tax asset	4,043,616	4,089,682
Total deferred income tax assets	27,497,608	24,368,849
Right-of-use asset	(93,875)
Depreciation	(670,176)	(583,812)
Deferred tax asset, net	26,733,557	23,785,037
Less: valuation allowance	(26,733,557)	(23,785,037)
Net deferred tax assets

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Effective Income Tax Rate Reconciliation [Line Items]
Deferred Tax Assets, Valuation Allowance	$ 26,733,557	$ 23,785,037
Operating loss carryforwards	$ 84,100,000
Expiration description	begin to expire in 2033
Income Taxes Receivable	$ 800,000
Income tax description	greater than 50 percent likelihood
Domestic Tax Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Income Taxes Receivable	$ 700,000
State and Local Jurisdiction [Member]
Effective Income Tax Rate Reconciliation [Line Items]
Income Taxes Receivable	$ 900,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Mar. 01, 2024

Feb. 06, 2024

Jun. 01, 2023

Jan. 17, 2018

Feb. 28, 2026

Feb. 28, 2025

Mar. 31, 2024

Feb. 29, 2024

Jul. 31, 2019

Dec. 31, 2023

Dec. 31, 2022

Nov. 04, 2024

Apr. 23, 2018

Sep. 27, 2016

Operating Loss Carryforwards [Line Items]

Income tax penalties and interest paid

$ 7,300,000

$ 7,300,000

Notes payable

Initial notes payable

1,026,758

2,917,390

Repayments of debt

400,000

$ 150,000

CHSPCS [Member]

Operating Loss Carryforwards [Line Items]

Settlement amount

$ 1,300,000

Tegal Notes [Member]

Operating Loss Carryforwards [Line Items]

Notes payable

$ 462,500

$ 384,384

Initial notes payable

200,000

Repayments of debt

$ 43,750

Settlement Agreement [Member]

Operating Loss Carryforwards [Line Items]

Damages paid value

$ 1,200,000

Settlement Agreement [Member] | Monthly Payment Through March One Two Thousand Twenty Three [Member]

Operating Loss Carryforwards [Line Items]

Litigation Settlement, Amount Awarded from Other Party

$ 253,000

Secured from hospital operating and other

$ 164,000

Subsequent Event [Member] | Settlement Agreement [Member]

Operating Loss Carryforwards [Line Items]

Agreed to pay

$ 705,000

Periodic payment

$ 15,000

Description of settlement agreement

Company agreed to make periodic payments totaling $705,000 through September 2026 in full satisfaction of such judgments. The Company agreed to make an initial payment of $100,000 in February 2024 and monthly payments of $15,000 through September 2026 with additional payments of $85,000 in February 2025 and $55,000 in February 2026.

Initial payment

$ 100,000

$ 100,000

Additional payments

$ 55,000

$ 85,000

Florida Department of Revenue [Member]

Operating Loss Carryforwards [Line Items]

Income Tax Examination, Penalties and Interest Accrued

$ 900,000

Florida Department of Revenue [Member] | Subsequent Event [Member] | Stipulation Agreement [Member]

Operating Loss Carryforwards [Line Items]

Description of agreement terms

Company agreed to pay $

Agreed to pay

$ 645,909

Periodic payment

$ 15,000

Final payment

$ 480,909

Schedule of Discontinued Operat

Schedule of Discontinued Operation of Unaudited Balance Sheet and Operation Statement (Details) - USD ($)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Accounts payable		$ 1,425,083	$ 1,425,083
Accrued expenses	[1]	7,666,630	520,051
Finance lease	[2]	220,461	220,461
Current liabilities of discontinued operations		9,312,174	2,165,595
Other (expense) income, net	[3]	(7,195,076)	56,844
Provision for income taxes
(Loss) income from discontinued operations		$ (7,195,076)	$ 56,844
[1]Included in accrued expenses at December 31, 2023 was $ 7.3 As of December 31, 2023 and 2022, the Company was in default under the finance lease obligation. Therefore, the aggregate future minimum lease payments under this finance lease totaling $ 0.2 7.3

Schedule of Discontinued Oper_2

Schedule of Discontinued Operation of Unaudited Balance Sheet and Operation Statement (Details) (Parenthetical) - USD ($)		12 Months Ended
		Dec. 31, 2023	Nov. 04, 2024	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Accrued expenses		$ 7,300,000	$ 7,300,000
Finance lease	[1]	220,461		$ 220,461
Other expense		$ 7,300,000
[1] As of December 31, 2023 and 2022, the Company was in default under the finance lease obligation. Therefore, the aggregate future minimum lease payments under this finance lease totaling $ 0.2

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Cash paid for interest	$ 419,177	$ 1,545,839
Cash paid for income taxes
Series F Preferred Stock converted into common stock		17,500
Stated value of Series N Preferred Stock converted into common stock	496,530	3,035,570
Stated value of Series O Preferred Stock converted into common stock	535,500	1,214,910
Deemed dividends from issuances of Series P Preferred Stock		333,333
Deemed dividends from down-round provisions of warrants		330,543,036
Non-cash interest income	90,653	212,819
Original issue discounts on debt		$ 50,000

Schedule of Warrants (Details)

Schedule of Warrants (Details) - Series B Warrants [Member]	Dec. 31, 2023 shares
March 21, 2024 to April 15, 2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants shares	1,350,000,000
April 16, 2024 to August 30, 2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants shares	2,500,000,000
August 31, 2024 to December 27, 2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants shares	4,000,000,000
December 28, 2024 to April 24, 2025 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants shares	4,000,000,000
April 25, 2025 to August 29, 2025 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants shares	4,000,000,000

Schedule of Pro-forma Balance S

Schedule of Pro-forma Balance Sheet Data (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Assets
Property and equipment, net	$ 4,321,299	$ 4,194,299
Investments in related parties	8,192,476	9,016,072
Total assets	20,252,940	20,572,762
Liabilities and stockholders’ deficit
Current liabilities of discontinued operations	9,312,174	2,165,595
Long-term debt	11,416,998	14,534,630
Total liabilities	57,096,480	49,667,350
Total stockholders’ deficit	(36,843,540)	(29,094,588)	$ (27,301,524)
Total liabilities and stockholders’ deficit	20,252,940	$ 20,572,762
Pro Forma [Member]
Assets
Related party notes receivable	5,603,543
Other current assets	875,216
Property and equipment, net	3,870,037
Investments in related parties	29,427,911
Other long-teem assets	739,647
Total assets	40,516,354
Liabilities and stockholders’ deficit
Account payable and accrued expenses	19,155,690
Debt (includes related party loan of $2.2 million)	2,570,926
Other current liabilities	638,681
Current liabilities of discontinued operations	9,312,174
Long-term debt	8,222,240
Other long-term liabilities	6,368,549
Total liabilities	46,268,260
Total stockholders’ deficit	(5,751,906)
Total liabilities and stockholders’ deficit	$ 40,516,354

Schedule of Unaudited Pro forma

Schedule of Unaudited Pro forma Dispositions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenue	$ 18,700,000	$ 13,000,000
Net loss from continuing operations	(534,085)	(3,349,899)
Deemed dividends		330,876,369
Net loss from continuing operations available to common stockholders	$ (7,729,161)	$ (334,169,424)
Net loss per common share:
Basic net loss from continuing operation available to common stockholders	$ 0	$ (0.03)
Diluted net loss from continuing operation available to common stockholders	$ 0	$ (0.03)
Pro Forma [Member]
Total revenue	$ 1,274,718	$ 1,529,651
Net loss from continuing operations	(4,639,798)	(4,697,805)
Deemed dividends		(330,876,369)
Net loss from continuing operations available to common stockholders	$ (4,639,798)	$ (335,574,174)

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)

1 Months Ended

8 Months Ended

12 Months Ended

Feb. 18, 2025

Oct. 25, 2024

Jun. 25, 2024

Jun. 17, 2024

Jun. 14, 2024

Jun. 13, 2024

Jun. 10, 2024

Jun. 01, 2024

Mar. 21, 2024

Feb. 06, 2024

Mar. 22, 2022

Sep. 30, 2026

Feb. 28, 2026

Feb. 28, 2025

Mar. 31, 2024

Feb. 29, 2024

Jul. 31, 2019

Sep. 10, 2024

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Feb. 03, 2025

Aug. 09, 2023

Principal amount

$ 100,000

Original issue discounts

$ 50,000

Issuance of debt

500,000

Reapyments of debt

400,000

150,000

Gain from forgiveness of debt

200,000

334,819

Accounts receivable, net

3,087,420

3,110,969

Purchase price

1,500,000

Promissory note

$ 1,026,758

$ 2,917,390

Preferred stock par value

$ 0.01

Consumer price percentage

90%

Series O Preferred Stock [Member]

Preferred stock par value

$ 0.01

$ 0.01

Issued shares

535.5

1,214.9

Stated value

$ 82

$ 87

Series B Warrant [Member]

Acquired common stock shares

101,300,000,000

March 2017 Debentures [Member]

Common stock exercisable

190,000,000,000

Exercise price per share

$ 0.00009

March 2017 Debentures [Member] | Series B Warrant [Member]

Common stock exercisable

127,600,000,000

2,500,000,000

Common stock exercisable termination

101,300,000,000

March 2017 Debentures [Member] | Series C Warrant [Member]

Common stock exercisable

190,000,000,000

Forecast [Member] | Series A Preferred Stock [Member]

Stated value

$ 8,000,000

Forecast [Member] | Series O Preferred Stock [Member]

Stated value

$ 8,000,000

Settlement Agreement [Member] | Forecast [Member]

Periodic payment

$ 15,000

Additional payments

$ 55,000

$ 85,000

Stipulation Agreement [Member] | Forecast [Member] | Florida Department of Revenue [Member]

Final payment

$ 480,909

Subsequent Event [Member]

Debt instruments interest rate

18%

Maturity date

Dec. 31, 2024

Subsequent Event [Member] | Promissory Note [Member] | Institutional Investors [Member]

Principal amount

$ 460,000

Original issue discounts percentage

15%

Original issue discounts

$ 60,000

Debt instruments interest rate

50%

Transferring of shares

350

Subsequent Event [Member] | Series B Warrant [Member]

Acquired common stock shares

23,800,000,000

Warrants expired

101,300,000,000

Subsequent Event [Member] | Series A Warrant [Member]

Acquired common stock shares

190,000,000,000

Subsequent Event [Member] | Series C Warrant [Member]

Acquired common stock shares

190,000,000,000

Subsequent Event [Member] | Settlement Agreement [Member]

Description of settlement agreement

Company agreed to make periodic payments totaling $705,000 through September 2026 in full satisfaction of such judgments. The Company agreed to make an initial payment of $100,000 in February 2024 and monthly payments of $15,000 through September 2026 with additional payments of $85,000 in February 2025 and $55,000 in February 2026.

Agreed to pay

$ 705,000

Initial payment

100,000

$ 100,000

Periodic payment

$ 15,000

Additional payments

$ 55,000

85,000

Subsequent Event [Member] | Stipulation Agreement [Member] | Florida Department of Revenue [Member]

Agreed to pay

$ 645,909

Periodic payment

$ 15,000

Final payment

$ 480,909

Subsequent Event [Member] | Sales Agreements [Member]

Issuance of debt

$ 1,100,000

Reapyments of debt

1,800,000

Gain from forgiveness of debt

700,000

Accounts receivable, net

$ 500,000

Subsequent Event [Member] | First Stock Exchange Agreement [Member] | Foxo Technologies Inc [Member]

Principal amount

$ 1,600,000

Promissory note

$ 300,000

Subsequent Event [Member] | First Stock Exchange Agreement [Member] | Common Class A [Member]

Purchase price

$ 200,000

$ 500,000

Equity interest shares

1,023,629

Promissory note

$ 300,000

Subsequent Event [Member] | Second Stock Exchange Agreement [Member] | Series A Preferred Stock [Member]

Principal amount

$ 22,000,000

Equity interest shares

20,000

Maturity date

Sep. 10, 2026

Consideration payable

$ 100

Interest description

The RCHI Note matured on September 10, 2026 and accrued interest on any outstanding principal amount at the rate of 8% per annum for the first six months, increasing to 12% per annum thereafter. After maturity, interest accrued at a rate of 20% per annum. The RCHI Note required principal repayments equal to 10% of the free cash flow (net cash from operations less capital expenditures) from RCHI and SCCH.

Preferred stock par value

$ 1

Share price

$ 1

Issued value

$ 21,000,000

Issued shares

21,000

Subsequent Event [Member] | Second Stock Exchange Agreement [Member] | New Senior Secured Promissory Note [Member] | Series A Preferred Stock [Member]

Principal amount

$ 1,000,000

Maturity date

Jun. 05, 2025

Subsequent Event [Member] | Myrtle And RCHI Agreement [Member]

Stated value

$ 8,000,000

Subsequent Event [Member] | Lease Agreement [Member]

Rental amount

$ 35,000

$ 65,000

Consumer price percentage

3%

3%

CHSPCS [Member]

Settlement amount

$ 1,300,000